Dosing regimen of an EGFR binding and / or complement activating antibody

Abstract

The disclosure relates to means and methods for administration of antibodies in the treatment of cancer. The disclosure in particular relates to a method of reducing infusion-related reactions in the treatment of a cancer in an individual with an EGER binding and / or complement activating antibody.

Description

[0001] Title: Dosing regimen of an EGFR binding and / or complement activating antibody FIELD OF THE INVENTION The disclosure relates to means and methods for administration of antibodies in the treatment of cancer. The disclosure in particular relates to a method of reducing infusion-related reactions in the treatment of a cancer in an individual with an EGFR binding and / or complement activating antibody. BACKGROUND OF THE INVENTION Cancer is still a major cause of death in the world, in spite of the many advances that have been made in the treatment of the disease and the increased knowledge of the molecular events that lead to cancer. Traditionally, most cancer drug discovery has focused on agents that block essential cell functions and kill dividing cells via chemotherapy. However, chemotherapy rarely results in a complete cure. In most cases, the tumors in the patients stop growing or temporarily shrink only to start proliferating again, some times more rapidly, and become increasingly more difficult to treat. Over the past decades, antibodies that specifically bind to oncogenic targets have been introduced and successfully used in numerous cancer treatments. For instance, monoclonal antibodies represent an important addition to the therapeutic options available to treat a variety of malignancies. However, many of these antibodies that are used for cancer therapy share a risk of the occurrence of infusion- related reactions (IRRs). Further, IRRs may be of such serious nature that treatment discontinuation may be needed, and can be life threatening. Historically, the most common drug classes associated with IRRs are the taxanes, platinum compounds and monoclonal antibodies (see e.g. Lenz, Management and Preparedness for Infusion and Hypersensitivity Reactions, The Oncologist 2007;12:601– 609). The reported incidence of mild-to-moderate reactions for monoclonal antibodies during the first infusion are for instance about 40% with trastuzumab, around 64% with any grade IRR for amivantamab, and up to 77% with rituximab. For cetuximab (Erbitux®), infusion reactions for Grades 3-4 are 2% as reported for patients with recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck (SCCHN). Across several studies, cetuximab was discontinued in 3–10% of patients because of such reactions. Prescribing information also includes a warning that infusion can cause serious and fatal infusion reactions. A similar warning is included in the prescribing information for rituximab. Strategies to mitigate IRRs depend on the grade of the reaction but generally involve slowing of infusion, immediate administration for treatment of symptoms. For Grade 3–4 reactions, mitigation involves stopping the infusion, immediate vigorous treatment of symptoms and contraindicate further use of cetuximab. A consequence of the occurrence of the highest grade reactions is unwanted discontinuation from treatment and thus less patients available for a possibly effective treatment. Prescribing information for amivantamab includes a split-dosing strategy where, depending on body weight of the subject, the prescribed dose is 1050 mg or 1400 mg antibody infused over two consecutive days. On the first day, a total of 350 mg is infused while on the following day the remainder of the prescribed dose is infused (i.e.700 mg). However, infusion of amivantamab still results in a considerable number of patients experiencing infusion related reactions and discontinuations from treatment of patients. Moreover, this approach creates significant discomfort and inconvenience for the patient, who must stay at or near an infusion center for prolonged periods of time. A need thus exists for mitigating or reducing the number of infusion-related reactions in subjects while being administered therapeutic antibodies, in particular in the treatment of cancer. The disclosure generally relates to methods that are usefulfor treating, preventing and / or mitigating infusion-related reactions (IRRs) inpatients treated with antibodies that comprise an EGFR binding arm and / or that are capable of activating complement. SUMMARY OF THE INVENTION The disclosure provides the following preferred aspects. However, the invention is not limited thereto. The present disclosure relates to antibodies, or a functional part thereof, that have an EGFR binding arm and / or which are capable of activating the complement system. In the present disclosure, the inventors demonstrate that the occurrence of infusion-related reactions could be reduced, mitigated and / or prevented when intravenously administering an antibody that comprises an EGFR binding arm in the treatment of a cancer when applying a dosing scheme as disclosed herein. Furthermore, the inventors show that the time to occurrence of the first infusion- related reactions could be delayed when intravenously administering an antibody that comprises an EGFR binding arm when applying a dosing scheme as disclosed herein, such as in comparison with the dosing scheme of Table 1. Thus, the present disclosure relates to the treatment of a cancer using a dosage regime which prevents or mitigates infusion-related reactions from intravenously infusing said antibody. The present disclosure relates to an antibody comprising an EGFR binding arm for use in treating cancer, by intravenously infusing a prescribed dose of the antibody comprising - a first infused amount of the antibody over a first infusion period using a first infusion rate, - a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate. The present disclosure also relates to an antibody comprising an EGFR binding arm for use in preventing or mitigating infusion-related reactions from intravenously infusing the antibody, comprising intravenously infusing a prescribed dose of the antibody using - a first infused amount of the antibody over a first infusion period using a first infusion rate, - a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate. The present disclosure also relates to a method of intravenously infusing a prescribed dose of an antibody comprising an EGFR binding arm comprising intravenously infusing - a first infused amount of the antibody over a first infusion period using a first infusion rate, - a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate. The present disclosure also relates to a method of mitigating or preventing the occurrence of infusion-related reactions from intravenous infusion of a prescribed dose of an antibody comprising an EGFR binding arm, the method comprising intravenously infusing - a first infused amount of the antibody over a first infusion period using a first infusion rate, - a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate. The present disclosure also relates to a method of treating a subject suffering from cancer with an antibody comprising an EGFR binding arm, the method comprising intravenously infusing a prescribed dose of said antibody using - a first infused amount of the antibody over a first infusion period using a first infusion rate, - a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate. In certain aspects, the first and second infusion periods are on the same day. In certain aspects, infusion of the prescribed dose of the antibody is completed on a single day. In certain aspect, the EGFR binding arm comprises or constitutes a variable domain that binds EGFR, such as a variable domain that binds an extracellular part of EGFR. In certain aspect, the antibody comprising an EGFR binding arm also comprises an LGR5 binding arm. In certain aspect, the LGR5 binding arm comprises or constitutes a variable domain that binds LGR5, such as a variable domain that binds an extracellular part of LGR5. In certain aspect, the antibody comprising an EGFR binding arm also comprises a cMET binding arm. In certain aspect, the cMET binding arm comprises or constitutes a variable domain that binds cMET, such as a variable domain that binds an extracellular part of cMET. In certain aspects, the EGFR, LGR5 and cMET binding arms bind specifically to EGFR, LGR5 and cMET, respectively. In certain aspects, the EGFR, LGR5 and cMET binding arms bind specifically to human EGFR, human LGR5 and human cMET, respectively. In certain aspects, the treatment or use further comprises administering an effective dose of a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist, such as zafirlukast, montelukast or pranlukast. Also, the present disclosure relates to the use of an antibody, or functional part thereof, of the present disclosure and a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist in the manufacture of one or more medicaments for treating a cancer in a subject. In certain aspects, the antibody or functional part thereof and the cysteinyl- leukotriene type 1 (CysLT1) receptor antagonist are used in the manufacture of the respective separate medicaments. In certain aspects, the treatment of cancer comprises intravenous infusion of the antibody or functional part thereof and orally administering the cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist. In certain aspects, the cancer comprises or is an adenocarcinoma, such as a squamous cell carcinoma. In certain aspects, the cancer comprises or is esophageal squamous cell carcinoma. In certain aspects, the cancer comprises or is a colorectal cancer, a pancreatic cancer, a lung cancer, a breast cancer, a liver cancer, a prostate cancer, an ovarian cancer, a cervical cancer, an endometrial cancer, a head and neck cancer, a melanoma, a testis cancer; a urothelial cancer, a renal cancer, a gastric cancer, an esophageal cancer, a gastric-esophageal-junction cancer, a brain cancer or a carcinoid cancer. In certain aspects, the cancer comprises or is a head and neck cancer. In certain aspects, the cancer comprises or is a squamous cell carcinoma of the head and neck (SCCHN). In certain aspects, the cancer comprises or is a cancer of the pharynx, the nasopharynx, the oropharynx, the hypopharynx, the larynx, the paranasal sinuses, the nasal cavity, the salivary glands or the oral cavity. In certain aspects, the cancer comprises or is a colorectal cancer. In certain aspects, the cancer comprises or is a gastric cancer, an esophageal cancer, a gastric- esophageal-junction cancer. In certain aspects, the antibody or functional part thereof, of the present disclosure comprises or is a multispecific antibody. In certain aspects, said antibody or functional part thereof, comprises or is a bispecific antibody. In certain aspects, the antibody, or functional part thereof, of the present disclosure is a multispecific antibody that comprises an EGFR binding arm. In certain aspects, said antibody, or functional part thereof, is a bispecific antibody that comprises an EGFR binding arm. In certain aspects, said antibody binds EGFR monovalently. In certain aspects, said antibody binds EGFR bivalently. In certain aspects, said antibody comprises a second binding arm that does not bind EGFR. In certain aspects, the antigen binding sites of said antibody consist of a first antigen binding site that binds an extracellular part of EGFR and a second antigen binding site that either binds EGFR, or does not bind to EGFR but specifically binds to a second target, such as cMET, LGR5 or EGFR. In certain aspects, said antibody or functional part thereof comprises an LGR5 binding arm. In certain aspects, an antibody of the present disclosure is an antibody capable of activating the complement system, in particular of activating the C1 complex. In certain aspects, an antibody of the present disclosure is capable of exhibiting complement-dependent cytotoxicity (CDC). In certain aspects, activation of the complement system occurs under permissible conditions. In certain aspects, said antibody is an IgG having an Fc tail which allows recruitment and activation of C1q. In certain aspects, said antibody is an IgG that binds monovalently to one of its binding epitopes, allowing formation of a hexagonal ring with five further monovalently binding IgG antibodies. In certain aspects, an antibody capable of complement activation comprises an EGFR binding arm. In certain aspects, said antibody is capable of forming a hexagonal ring with five further monovalently binding, or monovalently bound, IgG antibodies. In certain aspects, the antibody that comprises an EGFR binding arm comprises or is petosemtamab. In certain aspects, the antibody that comprises an EGFR binding arm comprises or is cetuximab. In certain aspects, the antibody that comprises an EGFR binding arm comprises or is amivantamab. In certain aspects, the antibody that comprises an EGFR binding arm is petosemtamab and is administered in a dose of 1500 mg. In certain aspects, petosemtamab is administered in a dose of 1500 mg once every two weeks. In certain aspects, an antibody, or functional part thereof, of the present disclosure is ADCC enhanced. Also, in certain aspects, an antibody or functional part thereof, of the present disclosure is afucosylated. In certain aspects, the cancer expresses EGFR and / or LGR5. In certain aspects, the cancer also expresses PD-L1. In certain aspects, the subject of the present disclosure is a mammalian subject, such as a human subject. The disclosure further comprises a (pharmaceutical) combination, or a kit-of- parts, that comprises an antibody, or functional part thereof, of the present disclosure combined with a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist. Said combination is in certain aspects not physically linked and may comprise a first container containing said antibody, or functional part thereof, and a second container containing said cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist. Said combination is in certain aspects accompanied by instructions for use. The instructions for use include clinically relevant information, such as instructions for intravenous infusion and oral administration, the dose to be infused and administered and the time interval of infusion and administration. In certain aspects, the antibody or functional part thereof, in particular petosemtamab, and said cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist are administered according to the instructions for use as mentioned herein. In certain aspects, said antibody, or a functional part thereof, comprises an EGFR binding arm and / or is capable of activating the complement system. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 Human LGR5 sequence. Figure 2 Human EGFR sequence. Figure 3 cMET sequence. Amino acid sequence full length human cMET insert for expression on the cell surface (Identical to UniProt entry:P08581-2). The sequence differs from the reference sequence at position with an insertion at 755-755: S → STWWKEPLNIVSFLFCFAS Figure 4. (a) Amino acid sequences of heavy chain variable regions that together with a common light chain variable region such as the variable region of the human kappa light chain IgVκ139*01 / IGJκ1*01 form a variable domain that binds EGFR. The CDR and framework regions are indicated in Figure 4b, following Kabat numbering. Figure 5. (a) Amino acid sequences of heavy chain variable regions that together with a common light chain variable region such as the variable region of the human kappa light chain IgVκ139*01 / IGJκ1*01 form a variable domain that binds LGR5. The CDR and framework regions are indicated in Figure 5b, following Kabat numbering. Figure 6. (a) Amino acid sequences of heavy chain variable regions that together with a common light chain variable region such as the variable region of the human kappa light chain IgVκ139*01 / IGJκ1*01 form a variable domain that binds cMET. The CDR and framework regions are indicated in Figure 6b, following Kabat numbering. Figure 7. Amino acid sequence of a common light variable region (IGKV1-39 / jk1) and CDR1, CDR2 and CDR3 according to IMGT numbering. Amino acid sequence of a common light variable region (IGKV1-39 / jk5) and CDR1, CDR2 and CDR3 according to IMGT numbering. Amino acid sequence of a light chain constant region. Figure 8. IgG heavy chains for the generation of bispecific molecules. a) CH1 region. b) Hinge region. c) CH2 region. d) CH3 domain containing variations L351K and T366K (KK). e) CH3 domain containing variations L351D and L368E (DE). Residue positions are according to EU numbering. DETAILED DESCRIPTION OF THE DISCLOSURE The present disclosure relates to methods to mitigate, reduce or prevent the occurrence of infusion-related reactions when intravenously administering or infusing an antibody that comprises an EGFR binding arm in the treatment of a cancer. Furthermore, the dosing regimens of the present disclosure are associated with a delayed time to the onset of infusion-related reactions when intravenously administering said antibody. In certain aspects, the dosing regimens as disclosed herein for administering said antibody permit not only the complete infusion of said antibody in a single day, but also leave sufficient time for a second therapeutic (e.g., an antibody) to be infused intravenously to the same subject on the same day. Consequently, a combination treatment that includes an antibody that binds EGFR and, e.g., an immune checkpoint inhibitor, such as pembrolizumab, can be started on a single day which is convenient for subjects as it diminishes the need for visits to hospitals or clinics for intravenous infusions. The disclosure provides a method of reducing occurrence or severity of infusion-related reactions (IRR) in a subject who is treated with an antibody that specifically binds an anti-epidermal growth factor receptor (EGFR) and optionally LGR5 or hepatocyte growth factor receptor (cMET). In a further aspect, the present disclosure relates to methods to mitigate, reduce or prevent the occurrence of infusion-related reactions when intravenously infusing an antibody that is used in the treatment of a cancer, which antibody is capable of activating the complement system, in particular of activating the C1 complex. C1 is the first component to be activated in the complement system, which after being activated, triggers the complement cascade. Activation of the complement system occurs under permissible conditions. In certain aspects, said antibody is an IgG having an Fc tail which allows recruitment and activation of C1q. In certain aspects, said IgG binds monovalently to one of its binding epitopes, allowing formation of a hexametric ring with five further monovalently binding IgG antibodies. In certain aspects, an antibody capable of complement activation comprises an EGFR binding arm. In a certain aspect, the present disclosure relates to an antibody comprising an EGFR binding arm, and optionally an LGR5 binding arm, for use in treating cancer, comprising intravenously infusing a first infused amount of the antibody over a first infusion period using a first infusion rate, a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate, wherein said intravenously infusing is for preventing, reducing or mitigating infusion-related reactions related to intravenously infusing said antibody. When intravenously infused, an antibody of the present disclosure that comprises an EGFR binding arm and / or which is capable of activating the complement system, can cause an infusion-related reaction (IRR). For instance, as reported in the United States Prescribing Information for RYBREVANT (amivantamab) (https: / / www.janssenlabels.com / package-insert / product- monograph / prescribing-information / RYBREVANT-pi.pdf), among 302 patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who received IV amivantamab at recommended Phase 2 dose (RP2D) as a single agent in the CHRYSALIS study, IRRs were among the most commonly occurring adverse events with an incidence of 66%. The present disclosure provides an improvement in the incidence of infusion related reactions for antibodies binding EGFR. The present disclosure relates to an antibody that comprises an EGFR binding arm and / or is capable of activating complement, for use in treating cancer in a subject, by intravenously infusing a prescribed dose of the antibody comprising - a first infused amount of the antibody over a first infusion period using a first infusion rate, - a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate. In certain aspects, the first and second infusion periods are on the same day. In certain aspects, infusion of the prescribed dose of the antibody is completed on a single day. Advantageously, on said single day, the subject is intravenously infused with a further medicament, such as pembrolizumab. In certain aspects, said further medicament, such as pembrolizumab, is administered subcutaneously. In certain aspects, the treatment further comprises the administration of an effective dose of a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist. Also, the present disclosure relates to a use of an antibody, or a functional part thereof, that binds at least EGFR and / or is capable of activating complement and a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist in the manufacture of one or more medicaments for treating a cancer in a subject. In certain aspects, the antibody, or functional part thereof, and the cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist are used to manufacture separate medicaments, such as two separate medicaments, one for said antibody, or functional part thereof, and one for said a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist. Said medicament comprising said antibody, or functional part thereof, of the present disclosure may be contained in a holder that is separate, meaning not physically linked, from a holder that contains said cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist as a medicament. In certain aspects, the treatment of cancer comprises administration of the antibody, or functional part thereof, of the present disclosure and the cysteinyl- leukotriene type 1 (CysLT1) receptor antagonist. In certain aspects, the present disclosure provides the use of an antibody, or a functional part thereof, that binds at least EGFR and / or is capable of activating complement and a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist in the manufacture of a medicament for the treatment of a cancer. In certain aspects, the present disclosure provides the use of a cysteinyl- leukotriene type 1 (CysLT1) receptor antagonist in the manufacture of a medicament for increasing the effect of an antibody that comprises an EGFR binding arm and / or is capable of activating complement for the treatment of cancer and / or for preventing or mitigating infusion-related reactions from intravenously infusing the antibody, or functional part thereof. Also, the present disclosure provides a kit-of-parts comprising an antibody, or functional part thereof, a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist and instructions for use of said antibody, or functional part thereof, that comprises an EGFR binding arm and / or is capable of activating complement and for use of said cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist. Also, the present disclosure provides a combination of an antibody, or functional part thereof, that comprises an EGFR binding arm and / or is capable of activating complement and a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist as mentioned herein for use in the treatment of cancer in a subject in need thereof and / or for preventing or mitigating infusion-related reactions from intravenously infusing said antibody, or functional part thereof. Also, the present disclosure provides a combination of a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist, as mentioned herein, instructions for use of said cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist in the treatment of cancer in a subject, as well as instructions for use in the treatment of said cancer of an antibody, or functional part, that binds at least EGFR and / or is capable of activating complement. Also, the present disclosure provides a combination of an antibody, or functional part thereof, that binds at least EGFR and / or is capable of activating complement, instructions for use of said antibody, or functional part thereof, in the treatment of cancer in a subject, as well as instructions for use in the treatment of said cancer in a subject of a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist. In certain aspects, the present disclosure provides a pharmaceutical composition comprising an antibody, or functional part thereof, that binds at least EGFR and / or is capable of activating complement and instructions for use thereof with a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist in the treatment of said cancer. In certain aspects, the present disclosure provides a pharmaceutical composition for the treatment of a cancer, comprising an antibody, or functional part thereof, that binds at least EGFR and / or is capable of activating complement and a pharmaceutical composition comprising a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist. In certain aspects, the present disclosure provides a pharmaceutical composition for use in the treatment of cancer comprising an antibody, or functional part thereof, that binds at least EGFR and / or is capable of activating complement, wherein the pharmaceutical composition is administered in combination with a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist. In certain aspects, the present disclosure relates to a pharmaceutical composition for the treatment of a cancer comprising an antibody, or functional part thereof, that binds at least EGFR and / or is capable of activating complement, wherein a subject to be treated is further administered a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist prior to intravenous infusion of said antibody. In certain aspects, the present disclosure relates to a pharmaceutical composition for the treatment of a cancer in a subject comprising a cysteinyl- leukotriene type 1 (CysLT1) receptor antagonist, wherein said subject to be treated is further administered an antibody, or functional part thereof, that binds at least EGFR and / or is capable of activating complement, after administration of said cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist. In certain aspects, said further administration of said antibody is subsequent to the administration of said cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist. In some aspects, the present disclosure thus relates to a combination of medicaments for the treatment of cancer in a subject which comprises administration to said subject of at least a first medicament and at least a second medicament for treating said cancer, which treatment comprises simultaneous, sequential or separate administration of said medicaments. In certain aspects, the first medicament comprises an antibody, or functional part thereof, that binds at least EGFR and / or is capable of activating complement, and the second medicament comprises a cysteinyl- leukotriene type 1 (CysLT1) receptor antagonist. In certain aspects, an antibody, or functional part thereof, that binds at least EGFR and / or is capable of activating complement may be administered simultaneously, sequentially or separately with the cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist of the present disclosure. In certain aspects, said administration is sequential. In certain aspects, said administration of said antagonist is prior to infusion of said antibody. Hence, in certain aspects, the present disclosure provides an antibody, or functional part thereof, that binds at least EGFR and / or is capable of activating complement for use in a method of treatment of a cancer, wherein the treatment further comprises administering a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist, wherein said antibody, or functional part thereof, is administered simultaneously, sequentially or separately with said cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist. In certain aspects, said administration is sequential. In certain aspects, said administration of said antagonist is prior to infusion of said antibody. Hence, in certain aspects, the present disclosure provides a method of treatment of a subject having a cancer, comprising administering to the subject an effective amount of a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist and an antibody, or functional part thereof, that binds at least EGFR and / or is capable of activating complement, wherein said antibody, or functional part thereof, is administered simultaneously, sequentially or separately with said cysteinyl- leukotriene type 1 (CysLT1) receptor antagonist. In some aspects, the present disclosure provides a combination therapy comprising the intravenous infusion of antibody, or functional part thereof, that binds at least EGFR and / or is capable of activating complement and a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist. In some aspects the antibody and antagonist are provided in separate formulations. Said antibody may be provided simultaneously, sequentially or separately from said antagonist. In certain aspects, said administration is sequential. In certain aspects, said antibody is provided after administration of said antagonist. Hence, in certain aspects, the present disclosure provides the use of antibody, or functional part thereof, that binds at least EGFR and / or is capable of activating complement and a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist in the manufacture of a medicament for the treatment of a cancer. In certain aspects, said antibody, or functional part thereof, is administered simultaneously, sequentially or separately with said cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist. In certain aspects, said administration of said antibody is after administration of said cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist. In certain aspects, an antibody, or functional part thereof, that binds at least EGFR and / or is capable of activating complement, is for use in the manufacture of a medicament for the treatment of a cancer and the cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist are for use in the manufacture of a medicament for the treatment of said cancer, wherein optionally said antibody, or functional part thereof, is administered simultaneously, sequentially or separately with said cysteinyl- leukotriene type 1 (CysLT1) receptor antagonist. In certain aspects, said administration of said cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist is prior to said antibody. In certain aspects, an antibody, or functional part thereof, that binds at least EGFR and / or is capable of activating complement is administered via an intravenous infusion. In certain aspects, the cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist is administered orally. In order that the present description may be more readily understood, certain terms are defined here. Additional definitions may be set forth throughout the detailed description where deemed required. Unless separately defined herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art, and conventional methods of immunology, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology are employed. As used herein, the singular forms "a", "an" and "the" include plural referents. Use of the term “comprising” “having” "including" as well as other forms, such as “comprise”, “comprises”, “comprised”, “has”, “have”, “had”, "include", "includes", and "included", is not limiting. The term “antibody” as used herein means a proteinaceous molecule belonging to the immunoglobulin class of proteins, containing one or more domains that bind an epitope on an antigen, where such domains are or derived from or share sequence homology with the variable region of an antibody. Antibodies are typically made of basic structural units, each with two heavy chains and two light chains. An antibody according to the present invention is not limited to any particular format or method of producing it. A “bispecific antibody” is an antibody as described herein wherein one domain of the antibody binds to one antigen whereas a further domain of the antibody binds to a further antigen, wherein said one and further antigens are not identical, or where one domain binds one epitope on an antigen, whereas a further domain binds to a further epitope on the antigen. The term “bispecific antibody” also encompasses antibodies wherein one heavy chain variable region / light chain variable region (VH / VL) combination binds an antigen or epitope on an antigen and a further VH / VL combination that binds a further antigen or epitope on the antigen. The term further includes antibodies wherein VH is capable of specifically recognizing one antigen and the VL, paired with the VH in an immunoglobulin variable region, is capable of specifically recognizing a further antigen. The resulting VH / VL pair will bind either antigen 1 or antigen 2. Such so called “two-in-one antibodies”, described in for instance WO 2008 / 027236, WO 2010 / 108127 and Schaefer et al (Cancer Cell 20, 472- 486, October 2011). A bispecific antibody according to the present invention is not limited to any particular bispecific format or method of producing it. The term “common light chain” as used herein refers to the two light chains (or the VL part thereof) in the bispecific antibody. The two light chains (or the VL part thereof) may be identical or have some amino acid sequence differences while the binding specificity of the full-length antibody is not affected. The terms “common light chain”, “common VL”, “single light chain”, “single VL”, with or without the addition of the term “rearranged” are all used herein interchangeably. “Common” also refers to functional equivalents of the light chain of which the amino acid sequence is not identical. Many variants of said light chain exist wherein mutations (deletions, substitutions, insertions and / or additions) are present that do not influence the formation of functional binding regions. In certain aspects, the light chain of the present invention can also be a light chain as specified herein, having from 0 to 10 amino acid insertions, deletions, substitutions, additions or a combination thereof. In certain aspects, said 0 to 10 amino acid insertions, deletions, substitutions, additions or a combination thereof are not within the CDR regions. In certain aspects, the light chain of the present invention can also be a light chain as specified herein, having from 0 to 5 amino acid insertions, deletions, substitutions, additions or a combination thereof. It is for instance within the scope of the definition of common light chains as used herein, to prepare or find light chains that are not identical but still functionally equivalent, e.g., by introducing and testing conservative amino acid changes, changes of amino acids in regions that do not or only partly contribute to binding specificity when paired with the heavy chain, and the like. As used herein, "to comprise" and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition, the verb “to consist” may be replaced by “to consist essentially of” meaning that a compound or adjunct compound as defined herein may comprise additional component(s) than the ones specifically identified, said additional component(s) not altering the unique characteristic of the invention. “Percent (w / w) (%) identity” as referring to nucleic acid or amino acid sequences herein is defined as the percent (w / w)age of residues in a candidate sequence that are identical with the residues in a selected sequence, after aligning the sequences for optimal comparison purposes. The percent (w / w) sequence identity comparing nucleic acid sequences is determined using the AlignX application of the Vector NTI Advance^11.5.2 software using the default settings, which employ a modified ClustalW algorithm (Thompson, J.D., Higgins, D.G., and Gibson T.J., (1994) Nuc. Acid Res. 22(22): 4673-4680), the swgapdnamt score matrix, a gap opening penalty of 15 and a gap extension penalty of 6.66. Amino acid sequences are aligned with the AlignX application of the Vector NTI Advance^11.5.2 software using default settings, which employ a modified ClustalW algorithm (Thompson, J.D., Higgins, D.G., and Gibson T.J., (1994) Nuc. Acid Res. 22(22): 4673-4680), the blosum62mt2 score matrix, a gap opening penalty of 10 and a gap extension penalty of 0.1. As an antibody typically recognizes an epitope of an antigen, and such an epitope may be present in other compounds as well, antibodies according to the present invention that “specifically recognize” an antigen or “specifically bind” a target, for example, PD-L1, EGFR, cMET or LGR5, may recognize other compounds as well, if such other compounds contain the same kind of epitope. Hence, the terms “specifically recognizes” with respect to an antigen and antibody interaction does not exclude binding of the antibodies to other compounds that contain the same kind of epitope. In certain aspects, an antibody of the present disclosure that binds EGFR is an antibody that specifically binds EGFR. In certain aspects, an antibody of the present disclosure that binds LGR5 is an antibody that specifically binds LGR5. In certain aspects, an antibody of the present disclosure that binds cMET is an antibody that specifically binds cMET. The term “epitope” or “antigenic determinant” refers to a site on an antigen to which an immunoglobulin or antibody specifically binds. Epitopes can be formed both from contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of a protein (so-called linear and conformational epitopes). Epitopes formed from contiguous, linear amino acids are typically retained on exposure to denaturing solvents, whereas epitopes formed by tertiary folding, conformation are typically lost on treatment with denaturing solvents. An epitope may typically include 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids in a unique spatial conformation. As used herein, the terms "subject" and "patient" are used interchangeably and refer to a mammal such as a human, mouse, rat, hamster, guinea pig, rabbit, cat, dog, monkey, cow, horse, pig and the like (e.g., a patient, such as a human patient, having cancer). The terms “treat,” “treating,” and “treatment,” as used herein, refer to any type of intervention or process performed on, or administering an active agent or combination of active agents to the subject with the objective of reversing, alleviating, ameliorating, inhibiting, or slowing down or preventing the progression, development, severity or recurrence of a symptom, complication, condition or biochemical indicia associated with a disease. Among active agents herein are therapeutic antibodies. As used herein, "effective treatment" or "positive therapeutic response" refers to a treatment producing a beneficial effect, e.g., amelioration of at least one symptom of a disease or disorder, e.g., cancer. A beneficial effect can take the form of an improvement over baseline, including an improvement over a measurement or observation made prior to initiation of therapy according to the method. For example, a beneficial effect can take the form of slowing, stabilizing, stopping or reversing the progression of a cancer in a subject at any clinical stage, as evidenced by a decrease or elimination of a clinical or diagnostic symptom of the disease, or of a marker of cancer. Effective treatment may, for example, decrease in tumor size, decrease the presence of circulating tumor cells, reduce or prevent metastases of a tumor, slow or arrest tumor growth and / or prevent or delay tumor recurrence or relapse. The term “effective amount” or “therapeutically effective amount” refers to an amount of an antibody or combination of antibodies that provides the desired biological, therapeutic, and / or prophylactic result. That result can be reduction, amelioration, palliation, lessening, delaying, and / or alleviation of one or more of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. In terms of tumor development, an effective amount is an amount sufficient to delay tumor development. In terms of tumor recurrence, an effective amount is an amount sufficient to prevent or delay tumor recurrence. An effective amount can be administered in one or more administrations. The effective amount of the antibody or composition may: (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, retard, slow to some extent and may stop cancer cell infiltration into peripheral organs; (iv) inhibit tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay occurrence and / or recurrence of tumor; and / or (vii) relieve to some extent one or more of the symptoms associated with the cancer. In one aspect, an “effective amount” is the amount of an antibody as disclosed herein as the antibody to affect a decrease in a cancer (for example a decrease in the number of cancer cells); slowing of progression of a cancer or prevent regrowth or recurrence of the cancer. An antibody of the present disclosure binds EGFR and / or is capable of complement activation. In certain aspects, the antibody is an antibody having anticancer activity. In certain aspects, the antibody comprises or is petosemtamab. In certain aspects, the effective amount of petosemtamab herein is a flat dose of 1500 mg administered on a biweekly basis to a subject. In certain aspects, the effective amount of petosemtamab herein is a flat dose of 1100 mg administered on a biweekly basis to a subject having a cancer of the present disclosure. In certain aspects, the antibody comprises or is cetuximab. In certain aspects, the effective amount of cetuximab herein is a dose of 400 mg / m2administered on a weekly basis to a subject. In certain aspects, the antibody of the present disclosure is or comprises amivantamab. In certain aspects, the effective amount of amivantamab herein is 1050 mg (for subject baseline body weight <80 kg) or 1400 mg (for subject baseline body weight ≥80 kg) IV once weekly for 4 weeks, then every 2 weeks thereafter. In certain aspects, the treatment described herein includes an immune checkpoint inhibitor. In certain aspects, the immune checkpoint inhibitor is or comprises pembrolizumab. As used herein, the term “prescribed dose” refers to a fixed dose of an antibody to be administered as part of a therapeutic treatment. In certain aspects, the prescribed dose in relation to petosemtamab is 1100 mg antibody. In certain aspects, the prescribed dose in relation to petosemtamab is 1500 mg antibody. Where the prescribed dose is used in relation to amivantamab, the prescribed dose is 1050 mg antibody or 1400 mg, depending on body weight of the subject to be treated. The prescribed dose for subjects weighing less than 80 kg is 1050 mg, while said dose for subjects of 80 kg or higher is 1400 mg. Where the prescribed dose is used in relation to cetuximab, the prescribed dose is 400 mg / m2antibody. In certain aspects, the prescribed dose is the same as the initial dose administered to a subject at the start of the therapeutic treatment of the present disclosure. In certain aspects, the prescribed dose in relation to pamvatamig is 1500 mg antibody. In certain aspects, the prescribed dose in relation to pamvatamig is 2000 mg antibody. In certain aspects, the prescribed dose in relation to pamvatamig is 3000 mg antibody. As used herein, the term “initial dose” is used in its common meaning, which refers to the first intravenously infused prescribed dose of antibody that is administered to a subject at the start of any anticancer treatment involving an antibody of the present disclosure that binds EGFR and / or is capable of activating the complement system. The initial dose is also referred to as the C1D1 dose. The initial dose may, for example, be included as part of a human clinical trial or included in the prescribing information once marketing approval has been obtained for treatment of one or more medical indications. Administration of an antibody typically follows a regular schedule of cycles (C) and days (D) comprising a number of intravenous infusions of the prescribed dose which follows a preset interval as part of a regular dosing regimen. For instance, a 28-day cycle wherein an antibody, such as petosemtamab, is administered once every two weeks, means that the initial dose (i.e. C1D1) begins with cycle 1 on day 1, the consecutive dose is administered on day 2 (i.e. C1D2), the next consecutive dose is administered again on day 1 (i.e. C2D1), the fourth consecutive dose is administered again on day 2 (i.e. C2D2) and so forth into cycle 3 and higher, as needed or desired. Typically, a subject to be treated according to the present disclosure has not been previously exposed to such an antibody. The subject may have undergone previous anticancer treatment but typically not with an antibody of the present disclosure, such as petosemtamab. Thus infusion of the initial dose typically constitutes the first exposure of the subject to said antibody. Also, it is the initial dose that is typically associated with occurrence of the majority of infusion related reactions. The initial dose as referred to herein is intravenously infused over two or more distinct infusion periods (herein referred to as the “first infusion”, the “second infusion” and so forth, optionally including at least a fifth infusion) to provide the prescribed dose of an antibody of the present disclosure. Infusion of said initial dose, or C1D1 dose, is typically for a time period of up to (and including) about 6 hours. In certain aspects, infusion of said initial dose, or C1D1 dose, is typically for a time period of up to (and including) about 5 hours. In certain aspects, infusion of said initial dose, or C1D1 dose, is typically for a time period of up to (and including) about 4 hours. Suitably, said infusion periods can be combined with a premedication as mentioned herein. Said initial C1D1 dose comprises infusion of the prescribed amount of an antibody of the present disclosure, such as 1100 mg or 1500 mg for petosemtamab, 1500 mg for pamvatamig, 400 mg / m2cetuximab, or 1050 mg or 1400 mg amivantamab. Dosing on subsequent scheduled treatment days, i.e. dosing which does not include C1D1 but any subsequent dosing including C1D2, C2D1. C2D2 etc,, is typically for a period of between (and up to) 1 and 6 hours. In certain aspects, said subsequent dosing is for a period of between 2 and 5 hours, or between 2 and 4 hours. As used herein, the term “first infusion” refers to an intravenous infusion of antibody which is a part of the initial dose to be administered. The first infusion is followed by a second infusion, or more such as a third, fourth and fifth infusion, which together make up the “initial dose” as referred to herein. The initial dose is administered to a subject as part of what is typically referred to in a human clinical setting as the C1D1 dose. The initial dose referred to herein is intravenously infused over multiple, separate infusion events, each having a specific infusion rate (expressed in mg antibody per hour), infusion period (expressed in hours) and amount of infused antibody (expressed in mg antibody). The infusions events will generally immediately follow each other. Throughout the specification and claims, wherever an infusion period having a higher ranked numerical value over an infusion period with a lower numerical value is mentioned, this indicates sequential infusions from the lower to the higher numerical values. For the avoidance of doubt, a first infusion, which comprises a first infused amount over a first infusion period using a first infusion rate, is followed by a second infusion, which comprises a second infused amount over a second infusion period using a second infusion rate. Subsequently, a third infusion may optionally follow, which comprises a third infused amount over a third infusion period using a third infusion rate. Subsequently, a fourth infusion may optionally follow, which comprises a fourth infused amount over a fourth infusion period using a fourth infusion rate. Subsequently, a fifth infusion may optionally follow, which comprises a fifth infused amount over a fifth infusion period using a fifth infusion rate. In certain aspects, said sequential infusions directly follow each other without any time in between infusion steps. In certain aspects, said sequential infusions follow each other with a minute or less time in between infusion steps. In certain aspects, said sequential infusions follow each other with 30 seconds or less time in between infusion steps. In certain aspects, said sequential infusions follow each other with 10 seconds or less time in between infusion steps. In certain aspects, said sequential infusions follow each other with 5 seconds or less time in between infusion steps. In certain aspects, a programmable infusion device (such as an injection pump) is used which allows infusion steps to follow each other immediately, without any time in between infusion steps. Thus, in certain aspects, said sequential infusions follow each without any time in between infusion steps. For the avoidance of doubt, it is emphasized that the initial dose refers to the sum of the first infused amount and second infused amount, or when present any optional remainder of the prescribed dose. The initial dose may thus also refer to the sum of the first, second and third infused amounts, or when present any optional remainder of the prescribed dose. The initial dose may thus also refer to the sum of the first, second, third and fourth infused amounts, or when present any optional remainder of the prescribed dose. The initial dose may thus also refer to the sum of the first, second, third, fourth and fifth infused amounts, or when present, any optional remainder of the prescribed dose. However if desired, the initial dose may also comprise one or more further infused amounts over a fifth infused amount. The sum of the infused amounts does not exceed the prescribed dose. The initial dose herein equals the prescribed dose and the initial dose only differs from other dosages in terms of timing of delivery as it the very first exposure of the antibody to the subject under the hereby disclosed treatment and thereby constitutes the start of treatment, unless stated otherwise or unless clear from the circumstances or context provided. An infusion-related reaction (IRR) is any unwanted medical occurrence that occurs in a subject due to the first intravenous infusion of the initial dose of an antibody of the present disclosure. In certain aspects, an infusion-related reaction herein relates to a group of signs and symptoms indicative of hypersensitivity reactions that occur during the infusion and up to 300 minutes or up to 24 hours after initiation of antibody infusion. In certain aspects, the IRRs are mild IRRs, manifesting as, but not limited to, chills, nausea, dyspnea, flushing, chest discomfort, hypotension, vomiting, tachycardia, fever, or any other symptoms during the time of the infusion or after the infusion. In certain aspects, the IRRs are systemic IRRs, including severe reactions, upon the introduction of a new therapeutic protein infusion, such as an EGFR binding antibody and / or an antibody capable of activating complement. In certain aspects, said IRRs occur in time from between immediately upon receiving the intravenous infusion up to about 300 minutes or 24 hours from the start of infusion. In certain aspects, the severity of IRRs is graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life- threatening and Grade 5= Death related to adverse event. In certain aspects, an adverse event comprises or is an infusion related event. In certain aspects, the presence of IRRs in a patient or subject is evaluated at Cycle 1 Day 1 of treatment with an antibody of the present disclosure. In certain aspects, the presence of IRRs in a patient or subject is evaluated at any time starting at Cycle 1 Day 1 and ending 30 days after end of treatment with said therapeutic antibody. In certain aspects, the presence of IRRs in a patient or subject is evaluated at Cycle 1 Day 1 of treatment with said therapeutic antibody. In certain aspects, the presence of IRRs in a patient or subject is evaluated at a time up to 3 month after the start of treatment with said therapeutic antibody. In certain aspects, the presence of IRRs in a patient or subject is evaluated at any time between 1 day to 30 days after end of treatment with said therapeutic antibody. In certain aspects, the presence of IRRs in a patient or subject is evaluated at any time between 1 day to 5 days after end of treatment with said therapeutic antibody. In certain aspects, the presence of IRRs in a patient or subject is evaluated at any time between 1 day to 10 days after end of treatment with said therapeutic antibody. In certain aspects, the presence of IRRs in a patient or subject is evaluated at any time between 1 day to 15 days after end of treatment with said therapeutic antibody. In certain aspects, the presence of IRRs in a patient or subject is evaluated at any time between 1 day to 20 days after end of treatment with said therapeutic antibody. In certain aspects, the first and second infused amount in sum is the prescribed dose. In certain aspects, the first, second and third infused amount in sum is the prescribed dose. In certain aspects, the first, second, third and fourth infused amount in sum is the prescribed dose. In certain aspects, the first, second, third, fourth and fifth infused amount in sum is the prescribed dose. In certain aspects, the first and second infused amount in sum is the initial dose or C1D1 dose. In certain aspects, the first and second infused amount, and any optionally remaining amounts such as a third, fourth and fifth infused amount, in sum constitute the initial dose or C1D1 dose. In certain aspects, the first, second and third infused amount in sum is the initial dose or C1D1 dose. In certain aspects, the first, second, third and fourth infused amount in sum is the initial dose or C1D1 dose. In certain aspects, the first, second, third, fourth and fifth infused amount in sum is the initial dose or C1D1 dose. In certain aspects, the first and second infused amount in sum, and any optionally remaining amounts such as a third, fourth and fifth infused amount, constitute the prescribed dose of an antibody that comprises an EGFR binding arm and / or is capable of activating complement. In certain aspects, said prescribed dose is 1100 mg or 1500 mg and the antibody is petosemtamab and the first and second infused amount in sum are the initial dosing of petosemtamab as administered to a subject. In certain aspects, the first and second infused amount in sum constitute the initial dose as administered to a subject of an antibody that comprises an EGFR binding arm and / or is capable of activating complement. In certain aspects, said initial dose is the dose as prescribed for cetuximab (such as 400 mg / m2) or amivantamab (such as 1050 mg antibody) and the first and second infused amount in sum are the initial dose of said antibodies as administered to a subject. In certain aspects, the first, second, third, fourth and fifth infused amount in sum constitute the initial dose as administered to a subject of an antibody disclosed herein. In certain aspects, said initial dose is the dose as prescribed for cetuximab (such as 400 mg / m2), amivantamab (such as 1050 mg or 1400 mg antibody) or petosemtamab as administered to a subject which has not previously been exposed to an antibody that binds EFGR, such as cetuximab, amivantamab or petosemtamab. In certain aspects, the first infused amount comprises about 0.5 to about 4 wt% (w / w) of the total amount of the antibody of the prescribed dose, from 1 to about 2 wt% (w / w), about 1 wt% (w / w) or about 2 wt% (w / w) of the prescribed dose. In certain aspects, the first infusion period is from about 15 to about 75 minutes, from about 30 to about 60 minutes, about 30 minutes or is about 60 minutes. In certain aspects, the first infused amount comprises from about 5 to about 50 mg antibody, from about 15 to about 30 mg antibody, about 15 or about 30 mg antibody. In certain aspects, the first infusion rate is from about 20 to about 40 mg antibody per hour, or about 30 mg antibody per hour. In certain aspects, the second infusion period is longer than or equal to the first infusion period. In certain aspects, the second infused amount of antibody is higher than the first infused amount. In certain aspects, infusion of the first and second infused amount of the antibody is completed on a single day. Using such a second infusion period markedly reduced the incidence and severity of infusion-related reactions and delayed the time to a first infusion-related reaction to occur, as evidenced by the results mentioned in the Examples. In certain aspects, the second infused amount comprises from about 96 to about 99.5 wt% of the prescribed dose, or about 98 wt% of the prescribed dose. In certain aspects, the second infusion period is from about 200 to about 300 minutes, from about 250 to about 260 minutes, or about 245 minutes. In certain aspects, the second infusion period is about 245 minutes. In certain aspects, the second infused amount comprises about 1450 to about 1495 mg, about 1470 mg of the antibody or the remainder of the prescribed dose of the antibody. In certain aspects, the second infused amount comprises about 1470 mg of the antibody. In certain aspects, the second infusion rate is from about 300 to about 400 mg antibody per hour, from about 360 to about 370 mg antibody per hour, or about 362.5 mg antibody per hour. In certain aspects, 24 hours before the start of infusing the first infused amount of the antibody, dexamethasone is administered. In certain aspects, one hour before the start of the infusion, each subject is administered dexamethasone; a compound selected from dexchlorpheniramine, diphenhydramine and chlorpheniramine; a compound selected from ranitidine, famotidine and cimetidine; and paracetamol. In certain aspects, 24 hours before the start of infusing the first infused amount of the antibody, 8 mg dexamethasone is administered PO. In certain aspects, said administration comprises dexamethasone 20 mg IV; and dexchlorpheniramine 5 mg IV, diphenhydramine 50 mg PO or chlorpheniramine 10 mg IV; and ranitidine 50 mg IV or 150 mg PO, famotidine 20 mg IV or cimetidine 300 mg IV; and paracetamol 1g IV or 650 mg PO. In certain aspects, the second infused amount comprises about 0.5 to about 4 wt% (w / w) of the total amount of the antibody of the prescribed dose, about 0.5 to about 2 wt% (w / w), or about 2 wt% (w / w). In certain aspects, the second infused amount comprises about 2 wt% (w / w). In certain aspects, the second infusion period is from about 15 to about 45 minutes or about 30 minutes. In certain aspects, the second infusion period is about 30 minutes. In certain aspects, the second infused amount comprises from about 20 to about 40 mg antibody, or about 30 mg antibody. In certain aspects, the second infused amount comprises about 30 mg antibody. In certain aspects, the second infusion rate is from about 20 to about 40 mg antibody per hour, or about 30 mg antibody per hour. In certain aspects, the second infusion rate is from about 20 to about 60 mg antibody per hour, In certain aspects, the second infusion rate comprises about 30 mg antibody per hour. In certain aspects, the second infusion rate comprises about 60 mg antibody per hour. In certain aspects, the method or use of the present disclosure further comprises infusing a third infused amount of the antibody over a third infusion period using a third infusion rate, wherein the third infused amount is higher than the second infused amount. In certain aspects, the third infusion period is longer than or equal to the second infusion period. In certain aspects, the third infusion rate is higher than the second infusion rate. In certain aspects, infusion of the first, second and third infused amount of the antibody is completed on a single day. In certain aspects, the third infused amount comprises about 2 to about 6 wt% (w / w) of the total amount of the prescribed dose or comprises about 4 wt% (w / w) of the total amount of the prescribed dose. In certain aspects, the third infused amount is administered over a period of about 15 to about 45 minutes, or a period of about 30 minutes. In certain aspects, the third infused amount comprises from about 40 to about 80 mg antibody, or about 60 mg antibody. In certain aspects, the third infusion rate is from about 100 to about 140 mg antibody per hour, or about 120 mg antibody per hour. In certain aspects, the third infused amount comprises about 4 wt% (w / w) of the total amount of the prescribed dose, the third infused amount is administered over a period of about 30 minutes, the third infused amount comprises about 60 mg antibody and the third infusion rate is about 120 mg antibody per hour. In certain aspects, the method or use of the present disclosure further comprises infusing a fourth infused amount of the antibody over a fourth infusion period using a fourth infusion rate, wherein the fourth infused amount is higher than the third infused amount. In certain aspects, the fourth infusion period is longer than or equal to the third infusion period. In certain aspects, the fourth infusion rate is higher than the third infusion rate. In certain aspects, infusion of the first, second, third and fourth infused amount of the antibody is completed on a single day. In certain aspects, the fourth infused amount comprises about 6 to about 20 wt% (w / w) of the total amount of the prescribed dose or comprises about 8 or about 16 wt% (w / w) of the total amount of the prescribed dose. In certain aspects, the fourth infused amount is administered over a period of about 15 to about 75 minutes, about 30 minutes or about 60 minutes. In certain aspects, the fourth infused amount comprises from about 100 to about 300 mg antibody, about 120 mg or about 240 antibody. In certain aspects, the fourth infusion rate is from about 200 to about 300 mg antibody per hour, or about 240 mg antibody per hour. In certain aspects, the fourth infused amount comprises about 8 wt% (w / w) of the total amount of the prescribed dose, the fourth infused amount is administered over a period of about 30 minutes, the fourth infused amount comprises about 120 mg antibody and the fourth infusion rate is about 240 mg antibody per hour. In certain aspects, the fourth infused amount comprises about 16 wt% (w / w) of the total amount of the prescribed dose, the fourth infused amount is administered over a period of about 60 minutes, the fourth infused amount comprises about 240 mg antibody and the fourth infusion rate is about 240 mg antibody per hour. In certain aspects, the method or use of the present disclosure further comprises infusing a fifth infused amount of the antibody over a fifth infusion period using a fifth infusion rate, wherein the fifth infused amount is higher than the fourth infused amount. In certain aspects, fifth infusion period is longer than or equal to the fourth infusion period. In certain aspects, fifth infusion rate is higher than the fourth infusion rate. In certain aspects, infusion of the first, second, third, fourth and fifth infused amount of the antibody is completed on a single day. In certain aspects, the fifth infused amount provides about 68 to about 91 wt% (w / w) of the prescribed dose, about 77 or about 85 wt% (w / w) of the prescribed dose. In certain aspects, the fifth infused amount is administered over a period of about 120 to about 240 minutes, about 158-162 minutes or about 190-196 minutes. In certain aspects, the fifth infused amount comprises about 1100 to 1300 mg of the antibody, about 1150 to about 1160 mg, about 1270 to about 1280 mg or the remainder of the prescribed dose of the antibody. In certain aspects, the fifth infusion rate is from about 300 to about 600 mg antibody per hour, about 340 to about 380 mg antibody per hour or about 450 to about 500 mg antibody per hour. In certain aspects, the fifth infused amount provides about 85 wt% (w / w) of the prescribed dose, the fifth infused amount is administered over a period of about 160 minutes, the fifth infused amount comprises about 1275 mg of the prescribed dose of the antibody and the fifth infusion rate is about 480 mg antibody per hour. In certain aspects, the fifth infused amount provides about 77 wt% (w / w) of the prescribed dose, the fifth infused amount is administered over a period of about 192.5 minutes, the fifth infused amount comprises about 1155 mg of the prescribed dose of the antibody and the fifth infusion rate is about 360 mg antibody per hour. Herein, these infused amounts relate to an antibody of the present disclosure, i.e. an antibody that comprises an EGFR binding arm and / or which is capable of activating complement. Inclusion of such third, fourth and fifth infusion periods markedly reduced the incidence and severity of infusion-related reactions and delayed the time to a first infusion-related reaction to occur, as evidenced by the results mentioned in the Examples. In certain aspects, -the first infused amount comprises from about 5 to about 50 mg antibody, from about 15 to about 30 mg antibody, about 15 or about 30 mg antibody and the first infusion rate is from about 20 to about 40 mg antibody per hour, or about 30 mg antibody per hour; - the second infused amount comprises about 1450 to about 1495 mg, about 1470 mg of the antibody and the second infusion rate is from about 300 to about 400 mg antibody per hour, from about 360 to about 370 mg antibody per hour, or about 362.5 mg antibody per hour In certain aspects, -the first infused amount comprises from about 5 to about 50 mg antibody, from about 15 to about 30 mg antibody, about 15 or about 30 mg antibody and the first infusion rate is from about 20 to about 40 mg antibody per hour, or about 30 mg antibody per hour; - the second infused amount comprises from about 20 to about 40 mg antibody, or about 30 mg antibody and the second infusion rate is from about 20 to about 40 mg or 60mg antibody per hour, or about 60 mg antibody per hour; - the third infused amount comprises from about 40 to about 80 mg antibody, or about 60 mg antibody and the third infusion rate is from about 100 to about 140 mg antibody per hour, or about 120 mg antibody per hour; - the fourth infused amount comprises from about 100 to about 300 mg antibody, about 120 mg and the fourth infusion rate is from about 200 to about 300 mg antibody per hour, or about 240 mg antibody per hour; and - the fifth infused amount comprises from about 1100 to 1300 mg of the antibody, about 1270 to about 1280 mg and the fifth infusion rate is from about 300 to about 600 mg antibody per hour, about 450 to about 500 mg antibody per hour. In certain aspects, -the first infused amount comprises from about 5 to about 50 mg antibody, from about 15 to about 30 mg antibody, about 15 or about 30 mg antibody and the first infusion rate is from about 20 to about 40 mg antibody per hour, or about 30 mg antibody per hour; - the second infused amount comprises from about 20 to about 40 mg antibody, or about 30 mg antibody and the second infusion rate is from about 20 to about 40 mg or 60 mg antibody per hour, or about 60 mg antibody per hour; - the third infused amount comprises from about 40 to about 80 mg antibody, or about 60 mg antibody and the third infusion rate is from about 100 to about 140 mg antibody per hour, or about 120 mg antibody per hour; - the fourth infused amount comprises from about 100 to about 300 mg antibody, about 240 antibody and the fourth infusion rate is from about 200 to about 300 mg antibody per hour, or about 240 mg antibody per hour; and - the fifth infused amount comprises from about 1100 to 1300 mg of the antibody, about 1150 to about 1160 mg and the fifth infusion rate is from about 300 to about 600 mg antibody per hour, about 340 to about 380 mg antibody per hour. In certain aspects, the combined infusion periods are more than 240 minutes, e.g., at least 250 minutes. In certain aspects, the combined infusion periods are at least 270 minutes. In certain aspects, the combined infusion periods are between 250- 500 minutes. In certain aspects, the combined infusion periods are between 250-400 minutes. For example, if the antibody, functional part, derivative and / or analogue thereof is provided as a first infused amount and a second infused amount, then the combined time of the first infusion period and second infusion period is at least 250 minutes, e.g., around 305 minutes. For example, if the antibody, functional part, derivative and / or analogue thereof is provided as a first, second, third, fourth, and fifth infused amount, then the combined time of the first, second, third, fourth, and fifth infusion period is at least 250 minutes, e.g., around 280 minutes, around 342.5 minutes or around 276 minutes. In certain aspects, infusion of the prescribed dose of the antibody is completed on a single day. In certain aspects, infusion of the prescribed dose of the antibody is within up to 6 hours on a single day. In certain aspects, the present disclosure relates to an antibody that comprises an EGFR binding arm, such as petosemtamab, and / or which is capable of activating complement, for use in the treatment of cancer in a subject, wherein said use comprises providing the subject with a flat dose of 1500 mg of the antibody, wherein said use comprises intravenously infusing said antibody over a period of at least 340 minutes, and wherein the first 345 mg of said antibody is intravenously infused over at least 150 minutes. In certain aspects, the present disclosure relates to an antibody that comprises an EGFR binding arm, such as petosemtamab, and / or which is capable of activating complement, for use in the treatment of cancer in a subject, wherein said use comprises providing the subject with a flat dose of 1100 mg of the antibody, and wherein said use comprises intravenously infusing said antibody over a period of at least 270 minutes, wherein the first 345 mg of said antibody is intravenously infused over at least 150 minutes. In certain aspects, the present disclosure relates to an antibody that comprises an EGFR binding arm, such as petosemtamab, and / or which is capable of activating complement, for use in the treatment of cancer in a subject, wherein said use comprises providing the subject with a flat dose of 1500 mg of the antibody, and wherein said use comprises intravenously infusing said antibody over a period of at least 275 minutes, wherein the first 105 mg of said antibody is intravenously infused over at least 90 minutes. In certain aspects, the present disclosure relates to an antibody that comprises an EGFR binding arm, such as petosemtamab, and / or which is capable of activating complement, for use in the treatment of cancer in a subject, wherein said use comprises providing the subject with a flat dose of 1500 mg of the antibody, and wherein said use comprises intravenously infusing said antibody for - a first infusion period of about 30 minutes at a rate of 30 mg / hours, - a second infusion period of about 30 minutes at a rate of 60 mg / hours, - a third infusion period of about 30 minutes at a rate of 120 mg / hours, and - a fourth infusion period of about 30 minutes at a rate of 240 mg / hours. In certain aspects, the present disclosure relates to an antibody that comprises an EGFR binding arm, such as petosemtamab, and / or which is capable of activating complement, for use in the treatment of cancer in a subject, wherein said use comprises providing the subject with a flat dose of 1500 mg of the antibody, and wherein said use comprises intravenously infusing said antibody for a first infusion period of at least about 30 minutes at a rate of about 30 mg / hours. In certain aspects, the present disclosure relates to an antibody that comprises an EGFR binding arm, such as petosemtamab, and / or which is capable of activating complement, for use in the treatment of cancer in a subject, wherein said use comprises providing the subject with a flat dose of 1500 mg of the antibody by intravenous infusion, wherein said infusion comprises a first infusion period of at least about 30 minutes at a rate of about 30 mg / hours. In certain aspects, the present disclosure relates to an antibody that comprises an EGFR binding arm, such as petosemtamab, and / or which is capable of activating complement, for use in the treatment of cancer in a subject, wherein a flat dose of 1500 mg of said antibody is provided to a subject by intravenous infusion, wherein said infusion comprises a first infusion period of at least about 30 minutes at a rate of about 30 mg / hours. In certain aspects, the present disclosure relates to an antibody that comprises an EGFR binding arm, such as petosemtamab, and / or which is capable of activating complement, for use in the treatment of cancer in a subject, wherein said use comprises providing the subject with a flat dose of 1500 mg of the antibody, wherein said use comprises intravenously infusing said antibody according to the schedule of Table 3. In certain aspects, a dosing and premedication regimen according to Example 4 is used during infusion of a subject. In certain aspects, a dosing regimen according to Table 3 is used during infusion of a subject. In certain aspects, the present disclosure relates to an antibody that comprises an EGFR binding arm and / or which is capable of activating complement, for use in the treatment of cancer in a subject, wherein said use comprises providing the subject with a flat dose of 1500 mg of the antibody, wherein said use comprises intravenously infusing said antibody according to the schedule of Table 5. In certain aspects, the antibody is petosemtamab. In certain aspects, prior to the first infused amount of antibody, the subject is administered an effective dose of a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist, including montelukast. In certain aspects, a dosing and premedication regimen according to Example 5 is used during infusion of a subject. In certain aspects, a dosing regimen according to Table 5 is used during infusion of a subject. In certain aspects, the present disclosure relates to an antibody that comprises an EGFR binding arm, such as petosemtamab, and / or which is capable of activating complement, for use in the treatment of cancer in a subject, wherein said use comprises providing the subject with a flat dose of 1500 mg of the antibody, wherein said use comprises intravenously infusing said antibody according to the schedule of Table 7. In certain aspects, prior to the first infused amount of antibody, the subject is administered an effective dose of a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist, including montelukast. In certain aspects, a dosing and premedication regimen according to Example 6 is used during infusion of a subject. In certain aspects, a dosing regimen according to Table 7 is used during infusion of a subject. In certain aspects, the present disclosure relates to an antibody that comprises an EGFR binding arm, such as petosemtamab, and / or which is capable of activating complement, for use in the treatment of cancer in a subject, wherein said use comprises providing the subject with a flat dose of 1100 mg of the antibody, wherein said use comprises intravenously infusing said antibody according to the schedule of Table 9. In certain aspects, prior to the first infused amount of antibody, the subject is administered an effective dose of a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist, including montelukast. In certain aspects, a dosing and premedication regimen according to Example 7 is used during infusion of a subject. In certain aspects, a dosing regimen according to Table 9 is used during infusion of a subject. In certain aspects, the present disclosure relates to an antibody that comprises an EGFR binding arm, such as petosemtamab, and / or which is capable of activating complement, for use in the treatment of cancer in a subject, wherein said use comprises providing the subject with a flat dose of 1500 mg of the antibody, wherein said use comprises intravenously infusing said antibody according to the schedule of Table 10. In certain aspects, prior to the first infused amount of antibody, the subject is administered an effective dose of a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist, including montelukast. In certain aspects, premedication Scheme 1 is used in a method or use according to the present disclosure to premedicate a subject. Premedication Dose, and route of administration Recommended dosing window priorinfusion of an antibody of the present disclosure, such as petosemtamab. A leukotrieneSuch as montelukast 10 mg, oral One dose, 2 days prior to infusion,receptor one dose one day prior to infusion, antagonist and one dose about one hour prior to infusion Aglucocorticoid Such as dexamethasone 8-10 mg, oral One dose, one day prior to infusionA glucocorticoid Such as dexamethasone 20 mg, IV One dose, on the day of infusion(such as within about one hour prior to infusion) An H11) Diphenhydramine 50 mg, oral orOne dose on the day of infusion (such antihistamine IV; as within about one hour prior to 2) Dexchlorpheniramine 10 mg IV;infusion) 3) Chlorpheniramine 20 mg IV or4) any equivalent of 1-3An H21) Ranitidine 50 mg oral or IV;One dose on the day of infusion (such antihistamine2) Ranitidine 50 mg IV with 150 mgas within about one hour prior to PO; infusion) 3) Famotidine 20 mg IV;4) Cimetidine 300 mg IV, or5) any equivalent of 1-4.An antipyretic Such as paracetamol (acetaminophen) One dose on the day of infusion (such 650 mg to 1000 mg, oral or IV as within about one hour prior to infusion) Premedication Scheme 1. Premedication scheme according to the present disclosure. Where the recommended window for dosing of a premedication component is mentioned, said window is meant relative to the day an antibody of the present disclosure is infused. For instance, where a subject is scheduled to receive for the first time a dose of an antibody of the present disclosure, such as petosemtamab (e.g. the C1D1 dosing), dosing of a leukotriene receptor antagonist takes place on the day which falls two days prior to said first scheduled day of dosing. Similarly, dosing of a glucocorticoid takes place on the day which falls one day prior to said first scheduled day of dosing. Similarly, dosing of an anti-histamine or an antipyretic takes place on the day of first scheduled dosing, such as within about one hour prior to infusion. In certain aspects, said antibody of the present disclosure which is infused is petosemtamab. In certain aspects, said antibody of the present disclosure which is infused is pamvatamig. In certain aspects, reducing IRRs associated with infusing an antibody of the present disclosure is meant in relation to an infusion scheme wherein the same antibody, comprised by the same amount of infusion volume is infused in a single infusion step using a flat dosing rate. In certain aspects, reducing IRRs associated with infusing an antibody of the present disclosure is meant in relation to an infusion scheme wherein 1500 mg of the same antibody, comprised by an infusion volume of 500 ml is infused in a single infusion step using an infusion rate of 125 ml per hour or 375 mg antibody per hour. In certain aspects, reducing IRRs associated with infusing an antibody of the present disclosure is meant in relation to the C1D1 infusion scheme as shown in Table 1 when infusing the same antibody in the same amount. In certain aspects, premedication (i.e. medication administered prior to infusion of the first amount of an antibody of the present disclosure) comprising the administration of dexamethasone, antihistamines and / or paracetamol is used in a method or use according to the present disclosure. In certain aspects, said premedication comprises administering of montelukast. In certain aspects, premedication (i.e. medication administered prior to infusion of the first amount of an antibody of the present disclosure) comprises administering 24 hours before the start of the infusion of said first amount of antibody, 8 mg of dexamethasone PO, followed by one hour before the start of infusion of said first amount of antibody, each patient will received dexamethasone 20 mg IV; and dexchlorpheniramine 5 mg IV, diphenhydramine 50 mg PO or chlorpheniramine 10 mg IV; and ranitidine 50 mg IV or 150 mg PO; and paracetamol 1g IV or 650 mg PO. In certain aspects, premedication (i.e. medication administered prior to infusion of the first amount of an antibody of the present disclosure) comprises administering 24 hours before the start of the infusion of said first amount of antibody, 8 mg of dexamethasone PO, followed by one hour before the start of infusion of said first amount of antibody, each patient will received dexamethasone 20 mg IV; and dexchlorpheniramine 10 mg IV or chlorpheniramine administered at 20 mg IV, diphenhydramine 50 mg PO or chlorpheniramine 10 mg IV; and famotidine administered at 20 mg IV; and paracetamol 1g IV or 650 mg PO. In certain aspects, premedication (i.e. medication administered prior to infusion of the first amount of an antibody of the present disclosure) comprising the administration of dexamethasone, antihistamines and / or paracetamol is used in a method or use according to the present disclosure. In certain aspects, said premedication comprises administering of montelukast. In certain aspects, said premedication comprises administering of montelukast. about 40 to 60 hours prior to start of infusion, such as at 10 mg orally (PO). In certain aspects, subsequently, within about 20 to 28 hours prior to start of infusion (such as about 24 hours), montelukast is administered, such as at 10 mg PO. In certain aspects, subsequently, about 2 hours to about 30 minutes (such as about one hour) prior to start of infusion of said antibody, montelukast is administered, such as at 10 mg PO. In certain aspects, said premedications are administered with infusion times of said initial antibody dose (or C1D1 dose) of about 2 hours. In certain aspects, said premedications are administered with infusion times of said initial antibody dose (or C1D1 dose) of about 3 hours. In certain aspects, said premedications are administered with infusion times of said initial antibody dose (or C1D1 dose) of about 4 hours. In certain aspects, said premedications are administered with infusion times of said initial antibody dose (or C1D1 dose) of about 5 hours. Epidermal growth factor (EGF) receptor (EGFR, ErbB1, or HER1) is a member of a family of four receptor tyrosine kinases (RTKs), named Her- or cErbB-1, -2, -3 and -4. EGFR is known under various synonyms, the most common of which is EGFR. EGFR has an extracellular domain (ECD) that is composed of four sub-domains, two of which are involved in ligand binding and two of which are involved in homo- dimerization and hetero-dimerization. EGFR integrates extracellular signals from a variety of ligands to yield diverse intracellular responses. A major signal transduction pathway activated by EGFR is composed of the Ras-mitogen-activated protein kinase (MAPK) mitogenic signaling cascade. Activation of this pathway is initiated by the recruitment of Grb2 to tyrosine phosphorylated EGFR. This leads to activation of Ras through the Grb2-bound Ras-guanine nucleotide exchange factor Son of Sevenless (SOS). In addition, the PI3-kinase-Akt signal transduction pathway is also activated by EGFR, although this activation is much stronger in case there is co-expression of ErbB-3 (HER3). The EGFR is implicated in several human epithelial malignancies, notably cancers of the breast, bladder, non-small cell lung cancer lung, colon, ovarian head and neck and brain. Activating mutations in the gene have been found, as well as over-expression of the receptor and of its ligands, giving rise to autocrine activation loops. This RTK has therefore been extensively used as target for cancer therapy. Both small-molecule inhibitors targeting the RTK and monoclonal antibodies (mAbs) directed to the extracellular ligand-binding domains have been developed and have shown hitherto several clinical successes, albeit mostly for a select group of patients. The database accession number for the human EGFR protein and the gene encoding it is GenBank NM_005228.3. This accession number is primarily given to provide a further method of identification of EGFR protein as a target, the actual sequence of the EGFR protein bound by an antibody may vary, for instance because of a mutation in the encoding gene such as those occurring in some cancers or the like. Where reference herein is made to EGFR, the reference refers to human EGFR unless otherwise stated. The variable domain antigen-binding site that binds EGFR, binds EGFR and a variety of variants thereof such as those expressed on some EGFR positive tumors. The term “LGR” refers to the family of proteins known as Leucine-rich repeat- containing G-protein coupled receptors. Several members of the family are known to be involved in the WNT signaling pathway, of note LGR4; LGR5 and LGR6. LGR5 is Leucine-Rich Repeat Containing G Protein-Coupled Receptor 5. Alternative names for the gene or protein are Leucine-Rich Repeat Containing G Protein-Coupled Receptor 5; Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 5; G-Protein Coupled Receptor HG38; G-Protein Coupled Receptor 49; G- Protein Coupled Receptor 67; GPR67; GPR49; Orphan G Protein-Coupled Receptor HG38; G Protein-Coupled Receptor 49; GPR49; HG38 and FEX. A protein or antibody of the invention that binds LGR5, binds human LGR5. The LGR5 binding protein or antibody of the invention may, due to sequence and tertiary structure similarity between human and other mammalian orthologs, also bind such an ortholog but not necessarily so. Database accession numbers for the human LGR5 protein and the gene encoding it are (NC_000012.12; NT_029419.13; NC_018923.2; NP_001264155.1; NP_001264156.1; NP_003658.1). The accession numbers are primarily given to provide a further method of identification of LGR5 as a target, the actual sequence of the LGR5 protein bound may vary, for instance because of a mutation in the encoding gene such as those occurring in some cancers or the like. Where reference herein is made to LGR5, the reference refers to human LGR5 unless otherwise stated. The LGR5 antigen binding site binds LGR5 and a variety of variants thereof, such as those expressed by some LGR5 positive tumor cells. Accession numbers are primarily given to provide a further method of identification of a target, the actual sequence of the protein bound may vary, for instance because of a mutation in the encoding gene such as those occurring in some cancers or the like. An antigen binding site of an antibody of the disclosure can bind the antigen and a variety of variants thereof, such as those expressed by some antigen positive immune or tumor cells. HGNC stands for the HUGO Gene nomenclature committee. The number following the abbreviation is the accession number with which information on the gene and protein encoded by the gene can be retrieved from the HGNC database. Entrez Gene provides the accession number or gene ID with which information on the gene or protein encoded by the gene can be retrieved from the NCBI (National Center for Biotechnology Information) database. Ensemble provides the accession number with which information on the gene or protein encoded by the gene can be obtained from the Ensemble database. Ensembl is a joint project between EMBL-EBI and the Wellcome Trust Sanger Institute to develop a software system which produces and maintains automatic annotation on selected eukaryotic genomes. An antibody, or functional part thereof, that binds EGFR and optionally LGR5. In certain aspects, an antibody, or functional part thereof, of the present disclosure comprises an EGFR binding arm. The phrase comprising “an EGFR binding arm” includes an antibody having “a variable domain that binds EGFR”. In certain aspects, “an EGFR binding arm” comprises an antigen binding site that consists of an antigen binding site that binds an extracellular part of EGFR. In certain aspects, said variable domain that binds EGFR comprises or is a variable domain that binds an extracellular domain of EGFR. In certain aspects, binding to EGFR is specific binding to EGFR, in particular specific binding to human EGFR. Such variable domains are described further herein. Similar meaning is given to an antibody having "an LGR5 binding arm”. In certain aspects, the antibody, or functional part thereof, further comprises a variable domain that binds an extracellular part of LGR5. In certain aspects, binding to LGR5 is specific binding to LGR5, in particular specific binding to human LGR5. Such variable domains are described further herein. In certain aspects, “an LGR5 binding arm” comprises an antigen binding site that consists of an antigen binding site that binds an extracellular part of LGR5. In certain aspects, the antibody, or functional part thereof, comprises a variable domain that binds an extracellular part of EGFR and a variable domain that binds an extracellular part of LGR5. In certain aspects, an antibody that comprises an EGFR binding arm and / or which is capable of activating complement comprises or is a multispecific antibody. In certain aspects, said antibody, or functional part thereof, comprises or is a bispecific antibody. Said multi- or bispecific antibody or a functional part thereof, in certain aspects comprises a variable domain that binds an extracellular part of the epidermal growth factor (EGF) receptor and a variable domain, which in certain aspects, does not bind EGFR. In certain aspects, the antibody, or functional part thereof, binds EGFR monovalently. Also, in certain aspects, said bispecific antibody, or functional part thereof, comprises a variable domain that binds LGR5. In certain aspects, said EGFR is a human EGFR. The EGFR that is bound by said antibody, or functional part thereof, of the present disclosure, includes wildtype EGFR as well as EGFR having an oncogenic driver mutation. In certain aspects, said oncogenic driver mutation is an activating EGFR mutation. In certain aspects, such a mutation does not conformationally change the epitope that is bound by the antibody of the present disclosure. In certain aspects, the variable domain binds LGR5. In certain aspects, the LGR5 is a human LGR5. The multispecific or bispecific antibody or a functional part thereof as described herein comprises a variable domain that binds an extracellular part of a human epidermal growth factor (EGF) receptor and in certain aspects, a variable domain that binds a human LGR5. Where herein accession numbers or alternative names of proteins / genes are given, they are primarily given to provide a further method of identification of the mentioned protein as a target, the actual sequence of the target protein bound by an antibody of the invention may vary, for instance because of a mutation and / or alternative splicing in the encoding gene such as those occurring in some cancers or the like. The target protein is bound by the antibody as long as the epitope is present in the protein and the epitope is accessible to the antibody. In certain aspects, the variable domain that binds human EGFR, is a variable domain with a heavy chain variable region that comprises at least the CDR1, CDR2 and CDR3 sequences of the VH of MF3755 as depicted in Figure 4; or the CDR1, CDR2 and CDR3 sequences of the VH of MF3755 as depicted in Figure 4 with at most three, or at most two, or at most one amino acid substitutions. In certain aspects, the variable domain that binds human EGFR, is a variable domain with a heavy chain variable region that comprises the sequence of the VH chain of MF3755 as depicted in Figure 4; or the amino acid sequence of the VH chain of MF3755 depicted in Figure 4 having at most 15 (or in certain aspects 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, or in certain aspects 1, 2, 3, 4 or 5) amino acid insertions, deletions, substitutions or a combination thereof with respect to the VH chain of MF3755. In certain aspects, said variable domain comprises a heavy chain variable region comprising at least the CDR1, CDR2 and CDR3 sequences of EGFR specific heavy chain variable region MF3755 as depicted in Figure 4. In certain aspects, the antibody comprising a variable domain that binds an extracellular part of EGFR and a variable domain that binds an extracellular part of LGR5, wherein the EGFR binding variable domain has a CDR1, CDR2, and CDR3 and / or a VH sequence as indicated herein above, and the variable domain that binds LGR5 comprises at least the CDR1, CDR2 and CDR3 sequence of LGR5 specific heavy chain variable region MF5816 as depicted in Figure 5. In certain aspects, the LGR5 variable domain comprises a heavy chain variable region comprising at least the CDR1, CDR2 and CDR3 sequences of LGR5 specific heavy chain variable region MF5816 as depicted in Figure 5. In certain aspects, said variable domain comprises a heavy chain variable region comprising at least the CDR1, CDR2 and CDR3 sequences of MF5816 as depicted in Figure 5. In certain aspects, the heavy chain variable region is MF5816. VH chains of variable domains that bind EGFR or LGR5 can have one or more amino acid substitutions with respect to the sequence depicted in figure 4 and 5. In certain aspects, a VH chain has an amino acid sequence of an EGFR or LGR5 VH of Figure 4 and 5, having at most 15, or 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 and, in certain aspects, having 1, 2, 3, 4 or 5 amino acid insertions, deletions, substitutions or a combination thereof with respect to the VH chain sequence of Figure 4 and 5. For instance, conservative amino acid substitution may be applied. Examples of conservative amino acid substitution include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another hydrophobic residue, and the substitution of one polar residue for another polar residue, such as the substitution of arginine for lysine, glutamic acid for aspartic acid, or glutamine for asparagine. In certain aspects, the mentioned at most 15 (or in certain aspects, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or in certain aspects 1, 2, 3, 4 or 5) amino acid substitutions in a VH or VL as specified herein are conservative amino acid substitutions. In certain aspects, the amino acid insertions, deletions and substitutions in a VH or VL as specified herein are not present in the CDR3 region. In certain aspects, the mentioned amino acid insertions, deletions and substitutions are also not present in the CDR1 and CDR2 regions. In certain aspects, the mentioned amino acid insertions, deletions and substitutions are also not present in the FR4 region. In certain aspects, the mentioned at most 15 (or in certain aspects, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, or in certain aspects 1, 2, 3, 4 or 5) amino acid substitutions are conservative amino acid substitutions. In certain aspects, the insertions, deletions, substitutions or a combination thereof are not in the CDR3 region of the VH chain, in certain aspects, not in the CDR1, CDR2 or CDR3 region of the VH chain and in certain aspects, not in the FR4 region. In certain aspects, the treatment of the present disclosure makes use of an antibody comprising a variable domain that binds an extracellular part of EGFR and a variable domain that, in certain aspects, binds an extracellular part of LGR5 comprises - the amino acid sequence of VH chain MF3755 as depicted in Figure 4; or - the amino acid sequence of VH chain MF3755 as depicted in Figure 4 having at most 15 (or in certain aspects, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, or in certain aspects 1, 2, 3, 4 or 5) amino acid insertions, deletions, substitutions or a combination thereof with respect said VH; and wherein the VH chain of the variable domain that binds LGR5 comprises - the amino acid sequence of VH chain MF5816 as depicted in Figure 5; or - the amino acid sequence of VH chain MF5816 as depicted in Figure 5 having at most 15 (or in certain aspects, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, or in certain aspects 1, 2, 3, 4 or 5) amino acid insertions, deletions, substitutions or a combination thereof with respect said VH. In certain aspects, the variable domain that binds an extracellular part of EGFR comprises a heavy chain variable region comprising the CDR1, CDR2 and CDR3 sequences of the variable region of MF3755 as depicted in Figure 4 and wherein the variable domain that binds an extracellular part of LGR5 comprises a heavy chain variable region comprising the CDR1, CDR2 and CDR3 sequences of the variable region of MF5816 as depicted in Figure 5. In certain aspects, the variable domain that binds an extracellular part of EGFR comprises a heavy chain variable region comprising the CDR1, CDR2 and CDR3 sequences of the variable region of MF3755 as depicted in Figure 4 and wherein the variable domain that binds an extracellular part of LGR5 comprises a heavy chain variable region comprising the CDR1, CDR2 and CDR3 sequences of the variable region of MF5816 as depicted in Figure 5. In certain aspects, a VH chain of the variable domain that binds EGFR comprises the amino acid sequence of VH chain MF3755 as depicted in Figure 4; or the amino acid sequence of VH chain MF3755 as depicted in Figure 4 having at most 15, preferably not more than 10, 9, 8 ,7, 6, 5, 4, 3, 2, 1 and preferably having not more than 5, 4, 3, 2 or 1 amino acid modifications, including insertions, deletions, substitutions or a combination thereof with respect said VH; and wherein a VH chain of the variable domain that binds LGR5 comprises the amino acid sequence of VH chain MF5816 as depicted in Figure 5; or the amino acid sequence of VH chain MF5816 as depicted in Figure 5 having at most 15, preferably not more than 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 and preferably having not more than 5, 4, 3, 2 or 1 amino acid modifications, including insertions, deletions, substitutions or a combination thereof with respect said VH. In certain aspects, a VH chain of the variable domain that binds EGFR comprises the amino acid sequence of VH chain MF3755 as depicted in Figure 4; and wherein a VH chain of the variable domain that binds LGR5 comprises the amino acid sequence of VH chain MF5816 as depicted in Figure 5. In certain aspects, both said variable domains that bind EGFR and that bind LGR5 comprise the CDR1, CDR2 and CDR3 regions of the light chain variable region as depicted in Figure 7. In certain aspects, both said variable domains that bind EGFR and that bind LGR5 comprise the light chain variable region as depicted in figure 7, which variable light chain region comprises from 0 to 10 amino acid insertions, deletions, substitutions, additions or a combination thereof, wherein the amino acid insertions, deletions and substitutions are not present in the CDR1, CDR2 and CDR3 light chain variable regions. The light chain variable regions of the VH / VL EGFR and LGR5 variable domains of the EGFR / LGR5 antibody may be the same or different. In certain aspects, the VL region of the VH / VL EGFR variable domain of the EGFR / LGR5 antibody is similar to the VL region of the VH / VL LGR5 variable domain. In certain aspects, VL regions in the VH / VL variable domains that bind EGFR and LGR5 are identical. In certain aspects, the light chain variable region of one or both VH / VL variable domains of the EGFR / LGR5 antibody comprises a common light chain variable region. In certain aspects, the common light chain variable region of one or both VH / VL variable domains comprises a germline IgVκ1-39 variable region V- segment. In certain aspects, the light chain variable region of one or both VH / VL variable domains comprises the kappa light chain V-segment IgVκ1-39*01. IgVκ1-39 is short for Immunoglobulin Variable Kappa 1-39 Gene. The gene is also known as Immunoglobulin Kappa Variable 1-39; IGKV139; IGKV1-39. External Ids for the gene are HGNC: 5740; Entrez Gene: 28930; Ensembl: ENSG00000242371. The amino acid sequence for a suitable V-region is provided in Figure 7. The V-region can be combined with one of five J-regions. In certain aspects, the J-regions are jk1 and jk5, and the joined sequences are indicated as IGKV1-39 / jk1 and IGKV1-39 / jk5; alternative names are IgVκ1-39*01 / IGJκ1*01 or IgVκ1-39*01 / IGJκ5*01 (nomenclature according to the IMGT database worldwide web at imgt.org). In certain aspects, the light chain variable region of one or both VH / VL variable domains comprises the kappa light chain IgVκ1-39*01 / IGJκ1*01 or IgVκ1-39*01 / IGJκ1*05 (described in Figure 7). In certain aspects, the light chain variable region of Figure 7 comprises LCDR1, LCDR2 and LCDR3 sequences. Such sequences can be determined or annotated by the skilled person using any suitable annotation system like IMGT, Chothia, Kabat or another annotation systems. In certain aspects, said light chain variable region is comprises by one or both VH / VL variable domains and present in an EGFR, LGR5 or cMET binding antibody of the present disclosure and comprise LCDR1, LCDR2 and LCDR3 sequences. In certain aspects, the light chain variable region of Figure 7 comprises LCDR1, LCDR2 and LCDR3 sequences as determined according to IMGT. In certain aspects, the light chain variable region of one or both VH / VL variable domains of the EGFR / LGR5 bispecific antibody comprises an LCDR1 comprising the amino acid sequence QSISSY (described in Figure 7), an LCDR2 comprising the amino acid sequence AAS (described in Figure 7), and an LCDR3 comprising the amino acid sequence QQSYSTPPT, i.e. the CDRs according to IMGT (as described in Figure 7). In certain aspects, a light chain comprises a light chain variable region with the amino acid sequence having at most 10, or at most 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9 amino acid insertions, deletions, substitutions or a combination thereof with respect to the indicated sequence. In certain aspects, said variable domain comprises a light chain variable region with the amino acid sequence having at most 0, 1, 2, 3, 4 or 5 amino acid insertions, deletions, substitutions or a combination thereof with respect to the indicated sequence. In certain aspects, the mentioned amino acid substitutions are conservative amino acid substitutions. In certain aspects, the insertions, deletions, substitutions or combination thereof are not in the CDR1, CDR2 or CDR3 region of the indicated VL chain. Also, the light chain variable region of one or both VH / VL variable domains of the EGFR / LGR5 antibody may comprise the amino acid sequence of a sequence as depicted in Figure 7. In certain aspects, both VH / VL variable domains of the EGFR / LGR5 antibody comprise identical VL regions. In certain aspects, the VL of both VH / VL variable domains of the EGFR / LGR5 bispecific antibody comprises the amino acid sequence set forth in Figure 7. Accordingly, in certain aspects, the heavy chain / light chain combination that comprises the variable domain that binds EGFR, comprises a DE variant of the heavy chain. In certain aspects, the heavy chain / light chain combination that comprises the variable domain that binds LGR5 comprises a KK variant of the heavy chain (such as described in Figure 8). An antibody as disclosed herein is typically a bispecific full length antibody, in certain aspects of the human IgG subclass. In certain aspects, said antibody is of the human IgG1 subclass. Such antibodies have good ADCC properties which can, if desired, be enhanced by techniques known in the art, have favorable half-life upon in vivo administration to humans and CH3 engineering technology exists that can provide for modified heavy chains that preferentially form heterodimers over homodimers upon co-expression in clonal cells. In certain aspects, a bispecific antibody as disclosed herein is ADCC enhanced. In certain aspects, such a bispecific antibody is afucosylated. In certain aspects, a bispecific antibody comprises a reduced amount of fucosylation of the N-linked carbohydrate structure in the Fc region, such as when compared to the same antibody produced in a normal CHO cell. Low fucose levels are associated with increased CD16 (FcγRIIIa) binding on NK effector cells, resulting in increased ADCC activity. In certain aspects, and in addition to its direct antitumor activity, a bispecific antibody of the present disclosure can eliminate tumor cells following opsonization and subsequent natural killer (NK) cell-mediated ADCC activity and CDC activity. In certain aspects, said Fc region is ADCC enhanced. In certain aspects, said Fc region is afucosylated. In certain aspects, ADCC functionality is enhanced by altering the Fc portion to increase binding affinity to FcγRIIIA. In certain aspects, ADCC functionality is enhanced by changing Fc region glycosylation. In certain aspects, ADCC functionality is enhanced by removing or reducing Fc region fucosylation. In certain aspects, the antibody is a bispecific antibody comprising two variable domains, wherein one variable domain binds an extracellular part of EGFR and another variable domain binds an extracellular part of LGR5. In certain aspects, the variable domains are variable domains as described herein. A functional part of an antibody as described herein comprises at least a variable domain that binds an extracellular part of EGFR. In certain aspects, said functional part comprises a variable domain that binds an extracellular part of LGR5 as described herein. In certain aspects, said functional part comprises a variable domain that binds an extracellular part of cMET as described herein. It thus comprises the antigen binding parts of an antibody as described herein and typically contains the variable domains of the antibody. A variable domain of a functional part can be a single chain Fv-fragment or a so-called single domain antibody fragment. In certain aspects, the antibody parts or derivatives have at least two variable domains of an antibody or equivalents thereof. In certain aspects, said functional part also comprises an Fc tail or a CH3 domain. In certain aspects, said Fc tail or CH3 region is an Fc tail or CH3 domain from a human IgG, such as from a human IgG1. Non- limiting examples of such variable domains or equivalents thereof are F(ab)- fragments and Single chain Fv fragments. A functional part of a bispecific antibody comprises the antigen binding parts of the bispecific antibody, or a derivative and / or analogue of the binding parts. As mentioned herein above, the binding part of an antibody is encompassed in the variable domain. The functional part, derivative and / or analogue maintains the binding specificity of the (bispecific) antibody. Binding specificity is defined by capacity to bind an extracellular part of EGFR, LGR5 and / or cMET as described herein. In certain aspects, said antibody, or functional part thereof, comprises petosemtamab (cf. Recommended INN list 83, WHO Drug Information Vol. 34, No. 1, 2020). In certain aspects, said antibody, or functional part thereof, comprises cetuximab. In certain aspects, said antibody, or functional part thereof, comprises amivantamab. Methods for determining or annotating CDR sequences of the indicated antibodies are known by the skilled person using for instance an annotation system like IMGT, Chothia, Kabat or other suitable annotation systems. In more detail, CDRs and framework regions of antibodies have been described and defined in the art using a number of different systems, including for instance Kabat (see Sequences of Proteins of Immunological Interest (National Institute of Health, Bethesda, Md., 1987 and 1991); Kabat et al., J. Biol. Chem.252:6609-6616 (1977)), IMGT (discussed in Giudicelli et al., Nucleic Acids Res.25: 206-2111997), Chothia (Chothia and Lesk J. Mol. Biol. 196: 901 -917, 1987; Chothia et al., Nature 342: 877-883, 1989; Al-Lazikani et al., J. Mol. Biol.273: 927-948, 1997), and the nomenclatures of Honnegher and Plukthun (Honnegher and Plukthun, J. Mol. Biol.309: 657-670, 2001), MacCallum (MacCallum et al., J. Mol. Biol.262:732-745 (1996); Abhinandan and Martin, Mol. Immunol., 45: 3832-3839 (2008)), and Lefranc (Lefranc M.P. et al., Dev. Comp. Immunol., 27: 55-77 (2003)). In general, it is irrelevant which numbering system is used, as an antibody exhibits its properties regardless of the numbering system used. When the amino acid sequence of a variable region is given, a skilled person can readily determine its CDRs based on different numbering systems. Thus, the present disclosure encompasses defining the CDRs in accordance with each numbering system available to a skilled person. In particular, the present disclosure encompasses defining the CDRs in accordance with the numbering systems of Kabat, IMGT, and Chothia. In certain aspects, the CDRs are as defined in Figure 4, 5, 6 or 7. In certain aspects, heavy chain CDRs are defined using Kabat, such as in Figures 4, 5 and 6. In certain aspects, light chain CDRs are defined using IMGT, such as in Figure 7. Amino acids in the constant regions are indicated according to the EU numbering system. In certain aspects, the present discourse relates to a medical use of an antibody in therapy, wherein the antibody is capable of activating complement. In certain aspects, the antibody is capable of exerting or displaying CDC. In certain aspects, said antibody is capable of activating the complement system, in particular of activating the C1 complex. Activation of the complement system occurs under permissible conditions, which conditions include a suitably functioning immune system of the subject to which said antibody is administered, or in particular a subject having a functional complement activation system which includes C1q and typically the downstream complement components to allow CDC to occur. In certain aspects, said suitably functioning immune system means the subject is capable of functional exhibiting CDC. In certain aspects, said antibody is an IgG having an Fc tail which allows recruitment and activation of C1q. In certain aspects, said IgG binds monovalently to one of its binding epitopes, allowing formation of a hexametric ring with five further monovalently binding IgG antibodies. In certain aspects, an antibody capable of complement activation comprises an EGFR binding arm. In certain aspects, said antibody is an IgG1, IgG2, IgG3 or IgG4. In certain aspects, an antibody capable of complement activation comprises an Fc tail or CH3 domain which comprises lysine as a residue on position 322 which allows C1q binding to an IgG (numbering is according to the EU numbering system). Complement activation herein can be established by measuring deposition of one of the downstream activated components of the CDC pathway, such as C3b. For instance, CDC activity can be measured using the Incucyte® CDC assay using suitable target cells that express a target of interest for an antibody of the present disclosure to bind to and allow it to display CDC activity. In certain aspects, said assay will be performed using 10-step semi-log dilutions of IgG to establish a concentration range in the presence of complement-preserved serum (e.g. from Sigma (cat #S1764-5x1ML). In certain aspects, measurements are performed every hour for 24 hour to establish CDC activity over said time points for the antibody of interest. In certain aspects, suitable target cells are A-431, CAL-27 or 293FF. In certain aspects, the CDC activity outcome is compared to a positive and / or a negative control sample. In certain aspects, the CDC activity outcome is compared to CDC activity of a well-investigated antibody such as cetuximab. In certain aspects, antibodies which are considered suitable for intravenous infusion using the herein disclosed dosing regimen include rituximab (Rituxan®, mouse chimeric IgG1 antibody which binds CD20, Biogen, Genentech, Hoffmann-La Roche, Chugai Pharmaceuticals, AryoGen), ofatumumab (Kesimpta®, Arzerra®, fully human IgG1 antibody which binds CD20, Novartis, Genmab), daratumumab (Darzalex®, fully human IgG1 antibody which binds CD38, Genmab, Johnson& Johnson), alemtuzumab (Campath®, Lemtrada®, humanized (from rat) IgG1 which binds CD52, Sanofi), or one of the following antibodies that comprise a binding arm that can bind or bind EGFR: panitumumab (Vectibix®, fully human IgG2 antibody, Amgen Inc.), necitumumab (Portrazza®, recombinant human IgG1 antibody, Eli Lilly and Company), AMG595 (fully human IgG1 antibody, Amgen Inc), nimotuzumab (BIOMAb-EGFR®, TheraCIM®, Theraloc®, CIMAher®, humanized (from mouse) IgG1 antibody, InnoKeys PTE Ltd.), BCA101 (humanized IgG1 antibody, Bicara Therapeutics), depatuxizumab (also known as ABT 806, humanized (from mouse) IgG1 antibody, Abbvie Inc), duligotuzumab (also known as MEHD7945A, humanized (from mouse) IgG1 antibody, Genentech, Roche), futuximab (also known as Sym004, mouse chimeric IgG1 antibody, Symphogen, Merck), GC1118 (fully human IgG1 antibody, Green Cross Corporation), imgatuzumab (also known as GA201, humanized (from mouse) IgG1 antibody, Roche), matuzumab (also known as EMD 72000, humanized (from mouse) IgG1 antibody, EMD Serono Inc., Merck), zalutumumab (HuMax-EGFR, fully human IgG1 antibody, Genmab A / S), HumMR1 (Chimeric monoclonal IgG1 antibody, Tabriz University of Medical Sciences), tomuzotuximab (mouse chimeric IgG1 antibody, Glycotope GmbH), LY3164530 (humanized IgG1 antibody, Eli Lilly & Company), Mab A13 (humanized IgG1 antibody, GC Biopharma), and AFM24 (IgG1-scFv fusion antibody, Affimed). An antibody, or functional part thereof, that binds EGFR and cMET. Aberrantly activated cMET may induce tumor growth, the formation of new blood vessels (angiogenesis) that supply the tumor with nutrients, and cancer spread to other organs (metastasis). cMET is deregulated in many types of human malignancies, including cancers of kidney, liver, stomach, breast, and brain. The cMET gene is known under a number of different names such as MET Proto- Oncogene, Receptor Tyrosine Kinase; Hepatocyte Growth Factor Receptor; Tyrosine- Protein Kinase Met; Scatter Factor Receptor; Proto-Oncogene C-Met; HGF / SF Receptor; HGF Receptor; SF Receptor; EC 2.7.10.1; Met Proto-Oncogene; EC 2.7.10; DFNB97; AUTS9; RCCP2; C-Met; MET; HGFR; External Ids for cMET are HGNC: 7029; Entrez Gene: 4233; Ensembl: ENSG00000105976; OMIM: 164860 and UniProtKB: P08581. The accession numbers are primarily given to provide a further method of identification of cMET protein as a target, the actual sequence of the cMET protein bound by an antibody may vary, for instance because of a mutation in the encoding gene such as those occurring in some cancers or the like. Where reference herein is made to cMET, the reference refers to human cMET unless otherwise stated. The antigen-binding site that binds cMET, binds cMET and a variety of variants thereof such as those expressed on some cMET positive tumors. In certain aspects, the present disclosure relates to a bispecific antibody that comprises an EGFR binding arm and a cMET binding arm. In certain aspects, the present disclosure relates to a bispecific antibody that comprises a first variable domain that can bind an extracellular part of human epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of human MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). In certain aspects, the antibody, or functional part thereof, comprises a cMET binding arm. The phrase comprising “a cMET binding arm” includes an antibody having “a variable domain that binds cMET”. In certain aspects, “a cMET binding arm” comprises an antigen binding site that consists of an antigen binding site that binds an extracellular part of cMET. In certain aspects, said variable domain that binds cMET comprises or is a variable domain that binds an extracellular domain of cMET. In certain aspects, binding to cMET is specific binding to cMET, in particular specific binding to human cMET. Such variable domains are described further herein. In certain aspects, the variable domain that binds EGFR comprises a heavy chain variable region with the amino acid sequence of MF8233 as depicted in Figure 4 having at most 10, or at most 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9 amino acid insertions, deletions, substitutions or a combination thereof with respect to the indicated sequence. In certain aspects, the variable domain that binds EGFR comprises a heavy chain variable region with the amino acid sequence of MF8233 having at most 0, 1, 2, 3, 4 or 5 amino acid insertions, deletions, substitutions or a combination thereof with respect to the indicated sequence. In certain aspects, said variable domain comprises CDR1, CDR2 and CDR3 amino acid sequences of the heavy chain variable region with the amino acid sequence of MF8233. In certain aspects, said variable domain comprises the heavy chain variable region with the amino acid sequence of MF8233. In certain aspects, the variable domain that binds cMET comprises a heavy chain variable region with the amino acid sequence of MF8230 as depicted in Figure 6 having at most 10, or at most 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9 amino acid insertions, deletions, substitutions or a combination thereof with respect to the indicated sequence. In certain aspects, said variable domain comprises a heavy chain variable region with the amino acid sequence of MF8230 having at most 0, 1, 2, 3, 4 or 5 amino acid insertions, deletions, substitutions or a combination thereof with respect to the indicated sequence. In certain aspects, said variable domain comprises CDR1, CDR2 and CDR3 amino acid sequences of the heavy chain variable region with the amino acid sequence of MF8230. In certain aspects, said variable domain comprises the heavy chain variable region with the amino acid sequence of MF8230. In certain aspects, the present disclosure relates to a bispecific antibody that comprises an EGFR binding arm and a cMET binding arm, wherein the EGFR binding arm comprises a variable domain that binds EGFR comprising CDR1, CDR2 and CDR3 amino acid sequences of a heavy chain variable region of MF8233 and the cMET binding arm comprises a variable domain comprising CDR1, CDR2 and CDR3 amino acid sequences of the heavy chain variable region of MF8230. In certain aspects, the present disclosure relates to a bispecific antibody that comprises an EGFR binding arm and cMET binding arm, wherein the EGFR binding arm comprises a variable domain that binds EGFR comprising a heavy chain variable region with the amino acid sequence of MF8233 and the cMET binding arm comprises a variable domain comprising a heavy chain variable region that comprises the amino acid sequence of MF8230. In certain aspects, the present disclosure relates to a bispecific antibody that comprises an EGFR binding arm and a cMET binding arm, wherein the EGFR binding arm comprises a variable domain that binds EGFR comprising CDR1, CDR2 and CDR3 amino acid sequences of a heavy chain variable region of MF3755 and the cMET binding arm comprises a variable domain comprising CDR1, CDR2 and CDR3 amino acid sequences of the heavy chain variable region of MF8230. In certain aspects, the present disclosure relates to a bispecific antibody that comprises an EGFR binding arm and cMET binding arm, wherein the EGFR binding arm comprises a variable domain that binds EGFR comprising a heavy chain variable region with the amino acid sequence of MF3755 and the cMET binding arm comprises a variable domain comprising a heavy chain variable region that comprises the amino acid sequence of MF8230. In certain aspects, the mentioned amino acid substitutions are conservative amino acid substitutions. In certain aspects, the insertions, deletions, substitutions or combination thereof are not in the CDR1, CDR2 or CDR3 region of the indicated VH chain. In certain aspects, the bispecific antibody of the present disclosure comprises pamvatamig (cf. WHO Drug Information, Vol. 37, No.2, 2023 Proposed INN: List 129). In certain aspects, the bispecific antibody of the present disclosure comprises the heavy and light chain CDR1, CDR2 and CDR3 amino acid sequences of pamvatamig. In certain aspects, the bispecific antibody of the present disclosure comprises the heavy chain and light chain amino acid sequences of pamvatamig. In certain aspects, the bispecific antibody of the present disclosure comprises amivantamab. In certain aspects, the bispecific antibody of the present disclosure comprises the heavy and light chain CDR1, CDR2 and CDR3 amino acid sequences of amivantamab. In certain aspects, the bispecific antibody of the present disclosure comprises the heavy chain and light chain amino acid sequences of amivantamab. Cysteinyl-leukotriene type 1 (CysLT1) receptor antagonists Next to the herein mentioned antibodies, the present disclosure also relates to the use of a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist, such as zafirlukast, montelukast and pranlukast. Cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist are a class of drugs that hinder the action of leukotriene by binding to the receptor with antagonistic action without having an agonistic effect. In certain aspects, prior to the intravenous infusion of the first infused amount of antibody, the subject is administered one or more effective doses of a cysteinyl- leukotriene type 1 (CysLT1) receptor antagonist, including zafirlukast, montelukast and pranlukast. For example, the subject may be administered an effective dose of said antagonist around 48 hours, around 24 hours, and around 1 hour prior to the intravenous infusion of the first infused amount of antibody. In certain aspects, prior to the intravenous infusion of the first infused amount of antibody, the subject is administered an effective dose of montelukast. In certain aspects, prior to the intravenous infusion of the first infused amount of antibody, the subject is administered an effective dose of pranlukast. In certain aspects, prior to the intravenous infusion of the first infused amount of antibody, the subject is administered an effective dose of zafirlukast. Montelukast is an oral medication, FDA-approved for the treatment of chronic asthma and prophylaxis and the prevention of exercise-induced bronchoconstriction. It is also approved for the relief of symptoms of both seasonal and perennial allergic rhinitis. Montelukast inhibits the mast cell mediated release of leukotrienes and may be used to reduce inflammation and bronchoconstriction. Montelukast is a highly selective leukotriene receptor antagonist that binds with high affinity to leukotrienes, which are excreted by various types of cells, including mast cells, and are involved in the inflammatory process that may cause the signs and symptoms of asthma and allergic rhinitis. In certain aspects, the CysLT1 receptor antagonist is montelukast and administration thereof is about 48 hours, about 24 hours and / or about 1 hour, prior to infusion of the first infused amount of the antibody. In certain aspects, montelukast is administered about 48 hours prior to infusion of the first infused amount of the antibody and administered about 24 hours prior to infusion of the first infused amount of the antibody and administered about 1 hour prior to infusion of the first infused amount of the antibody. In certain aspects, an amount of about 5 to about 15 mg montelukast is administered. In certain aspects, an amount of about 10 mg montelukast is administered. In certain aspects, montelukast is orally administered. Inclusion of a cysteinyl- leukotriene type 1 (CysLT1) receptor antagonist, in particular montelukast, markedly reduced the incidence and severity of infusion-related reactions as evidenced by the results mentioned in the Examples. Especially the number of subjects experiencing at least a single IRR or Grade 3 or higher IRR was reduced using montelukast. In certain aspects, montelukast is administered orally. In certain aspects, montelukast is administered as an injection. In certain aspects, montelukast is administered subcutaneously. In certain aspects, montelukast is administered intravenously. In certain aspects, montelukast is administered intramuscularly. In certain aspects, montelukast is administered prior to the treatment with an antibody of the present disclosure. In certain aspects, montelukast is administered 1-7 times prior to the treatment with said antibody. In certain aspects, montelukast is administered 1 time prior to the treatment with an antibody of the present disclosure. In certain aspects, montelukast is administered 2 times prior to infusion of an antibody of the present disclosure, such as the EGFR binding antibody. In certain aspects, montelukast is administered 3 times prior to infusion of an antibody of the present disclosure, such as an EGFR binding antibody. In certain aspects, montelukast is administered 4 times prior to infusion of an antibody of the present disclosure, such as an EGFR binding antibody. In certain aspects, montelukast is administered 5 times prior to infusion of an antibody of the present disclosure, such as an EGFR binding antibody. In certain aspects, montelukast is administered 6 times prior to infusion of an antibody of the present disclosure, such as an EGFR binding antibody. In certain aspects, montelukast is administered 7 times prior to infusion of an antibody of the present disclosure, such as an EGFR binding antibody. In certain aspects, montelukast is administered starting 5 days prior to infusion of an antibody of the present disclosure, such as an EGFR binding antibody. In certain aspects, montelukast is administered starting 4 days prior to infusion of an antibody of the present disclosure, such as an EGFR binding antibody. In certain aspects, montelukast is administered starting 3 days prior to infusion of an antibody of the present disclosure, such as an EGFR binding antibody. In certain aspects, montelukast is administered starting 2 days prior to infusion of an antibody of the present disclosure, such as an EGFR binding antibody. In certain aspects, montelukast is administered starting 2 days prior to infusion of an antibody of the present disclosure, such as an EGFR binding antibody, and 1 day prior to infusion of an antibody of the present disclosure, such as an EGFR binding antibody. In certain aspects, the last administration of montelukast is given on the first day of treatment with the EGFR binding antibody. In certain aspects, montelukast is administered at a dose of 4-20 mg. In certain aspects, montelukast is administered at a dose of 5-10 mg. In certain aspects, montelukast is administered at a dose of 4 mg. In certain aspects, montelukast is administered at a dose of 5 mg. In certain aspects, montelukast is administered at a dose of 8 mg. In certain aspects, montelukast is administered at a dose of 10 mg. In certain aspects, montelukast is administered at a dose of 15 mg. In certain aspects, montelukast is administered at a dose of 16 mg. In certain aspects, montelukast is administered at a dose of 20 mg. In certain aspects, a first dose of montelukast is administered 48 hours prior to the first infused amount of an antibody of the present disclosure. In certain aspects, said dose of montelukast is 4-20 mg, in particular about 10 mg, and said administration thereof is an oral administration. In certain aspects, a second dose of montelukast is administered 20-28 hours prior to first infused amount of an antibody of the present disclosure. In certain aspects, said second dose is administered about 24 hours prior to said initial infusion. In certain aspects, said second dose of montelukast is 4-20 mg, in particular about 10 mg and administration is orally. Said second dose may be administered in combination with an oral administration of about 8 mg dexamethasone. In certain aspects, a third dose of montelukast is administered about half an hour to two hours prior to the first infused amount of an antibody of the present disclosure. In certain aspects, said third dose is administered about 1 hour prior to said initial infusion. In certain aspects, said third dose of montelukast is 4-20 mg, in particular about 10 mg and administration is orally. Said third dose may be administered in combination with an intravenous infusion of about 20 mg dexamethasone. In certain aspects, said third dose of montelukast is administered in combination with an intravenous injection of dexchlorpheniramine of 10 mg or an oral administration of diphenhydramine of 50 mg or an intravenous injection of chlorpheniramine of 20 mg; and an intravenous injection of ranitidine of 50 mg, or an oral dose of ranitidine of 150 mg, or an intravenous injection of famotidine of 20 mg or an intravenous injection of cimetidine of 300 mg; and an intravenous injection of paracetamol of 1 g or an oral dose of paracetamol of 650 mg. In an alternative aspect, said third dose of montelukast is administered in combination with an intravenous injection of dexchlorpheniramine 10 mg or an oral dose of diphenhydramine of 50 mg or an intravenous injection of chlorpheniramine of 20 mg; and an intravenous injection of ranitidine of 50 mg or an oral dose of 150 mg ranitidine or an intravenous injection of famotidine of 20 mg or an intravenous injection of cimetidine of 300 mg; and an intravenous injection of paracetamol of 1 g or an oral dose of paracetamol of 650 mg. Administration of the antibody of the present disclosure may be premedicated, meaning medication is administered to the subject prior to being administered an antibody of the present disclosure. In certain aspects, intravenous infusion of petosemtamab is premedicated with an antihistamine, pain reducing medication, fever reducing medication and / or anti-inflammatory medication. Cancers of the present disclosure The terms cancer and tumor are used herein and typically both refer to cancer, unless otherwise specifically stated. Thus, as used herein, the term ‘cancer’ applies equally to the term ‘tumor’, such that treatment of a tumor also applies to treatment of a cancer. In certain aspects, the cancer comprises or is a colorectal cancer, a pancreatic cancer, a lung cancer, a breast cancer, a liver cancer, a prostate cancer, an ovarian cancer, a cervical cancer, an endometrial cancer, a head and neck cancer, a melanoma, a testis cancer; a urothelial cancer, a renal cancer, a gastric cancer, an esophageal cancer, a gastric-esophageal-junction cancer, a brain cancer or a carcinoid cancer. In certain aspects, the cancer comprises or is esophageal squamous cell carcinoma. In certain aspects, the cancer comprises or is an adenocarcinoma, a squamous cell carcinoma, or a head and neck cancer. In certain aspects, the cancer comprises or is a squamous cell carcinoma of the head and neck (SCCHN). In certain aspects, the cancer comprises or is a cancer of the pharynx, the nasopharynx, the oropharynx, the hypopharynx, the larynx, the paranasal sinuses, the nasal cavity, the salivary glands or the oral cavity. In certain aspects, the cancer comprises or is a colorectal cancer. In certain aspects, the cancer comprises or is a gastric cancer, an esophageal cancer, a gastric-esophageal-junction cancer. Cancers that are known collectively as head and neck cancers usually originate in the squamous cells that line the moist, mucosal surfaces inside the head and neck, such as inside the mouth, the nose, and the throat. These squamous cell cancers are often referred to as squamous cell carcinomas of the head and neck and said cancers are treated in certain aspects of the present disclosure. Although rare, head and neck cancers can also occur in the salivary glands. In certain aspects, the head and neck cancer may occur in the oral cavity. This includes the lips, the front two-thirds of the tongue, the gums, the lining inside the cheeks and lips, the floor of the mouth under the tongue, the hard palate, and the small area of the gum behind the wisdom teeth. Thus, in certain aspects, the head and neck cancer is squamous cell carcinoma and includes laryngeal cancer, hypopharyngeal cancer, nasal cavity cancer, paranasal sinus cancer, oral cancer, oropharyngeal cancer or salivary gland cancer. In certain aspects, the present disclosure relates to treatment of a cancer comprising a squamous cell head and neck cancer, such as located in the oropharynx, hypopharynx, the larynx, the oral cavity or the tongue. In certain aspects, the cancer comprises or is an adenocarcinoma, a squamous cell carcinoma, or a head and neck cancer, including squamous cell carcinoma of the head and neck (SCCHN). In certain aspects, the cancer is a squamous cell carcinoma of the head and neck. In certain aspects, the cancer is a squamous cell carcinoma of the head and neck that expresses EGFR and PD-L1. In certain aspects, the cancer is a squamous cell carcinoma that expresses EGFR and PD-L1. In certain aspects, the cancer is a cancer of the pharynx, including oropharynx and hypopharynx, oral cavity, larynx, paranasal sinuses, nasal cavity or salivary glands. In certain aspects, the cancer is a cancer of the oropharynx, oral cavity, hypopharynx or larynx. In certain aspects, the primary location of the cancer is in the oropharynx, oral cavity, hypopharynx or larynx. In certain aspects, the head and neck cancer is a squamous cell carcinoma of unknown primary (also referred to in the art as a cancer of unknown primary or CUP). In certain aspects, the cancer is locally advanced, unresectable or metastatic, such as head and neck squamous cell carcinoma. Administration, dosage regime and instructions for use In certain aspects, the present disclosure comprises instructions for use of said antibody, or functional part thereof, of the present disclosure that may bind EGFR and optionally LGR5, such as petosemtamab. These instructions for use are provided in more detail in the present disclosure and relate to indications for usage (such as for the treatment of head and neck cancer), route of administration (such as intravenous injection), dosage amount (such as an amount of 1500 mg), a dosage irrespective of body weight of the subject (i.e. a flat dose) and the dosage interval (such as once every two weeks). In certain aspects, said antibody, or functional part thereof, that binds EGFR comprises or is petosemtamab (cf. Recommended INN list 83, WHO Drug Information Vol. 34, No.1, 2020) and instructions for use include administration in an amount of 1500 mg as an intravenous infusion once every two weeks. In certain aspects, said dose is a flat dose of 1500 mg. In certain aspects, said antibody, or functional part thereof, that binds EGFR comprises or is petosemtamab and instructions for use include administration in an amount of 1100 mg as an intravenous infusion once every two weeks. In certain aspects, said dose is a flat dose of 1100 mg. As mentioned, dosing regimens as disclosed herein for administering an antibody of the present disclosure permit not only to complete the first intravenous infusion of petosemtamab on a single day, but also leaves sufficient time for a second antibody to be infused intravenously to the same subject on the same day. Consequently, a combination treatment that includes petosemtamab and an immune checkpoint inhibitor, such as pembrolizumab, is part of the present disclosure. In certain aspects, the immune checkpoint inhibitor is or comprises pembrolizumab. In certain aspects, pembrolizumab is administered subcutaneously. In certain aspects, subcutaneous administration of pembrolizumab is every six weeks according to FDA regulation. In certain aspects, petosemtamab and pembrolizumab are sequentially administered. In certain aspects, when pembrolizumab and petosemtamab are administered on the same day, pembrolizumab is administered after petosemtamab. In certain aspects, petosemtamab is administered in an amount of 1500 mg once every two weeks and pembrolizumab is administered in an amount of 400 mg once every six weeks. In certain aspects, both said dosages are a flat dose. In certain aspects, pembrolizumab is administered subcutaneously using said dose. In certain aspects, the immune checkpoint inhibitor is pembrolizumab and administered in an amount of 200 mg as an intravenous infusion every 3 weeks. In certain aspects, said administration is a flat dose of 200 mg and occurs every 3 weeks until disease progression or unacceptable toxicity. In certain aspects, the immune checkpoint inhibitor is pembrolizumab and administered in an amount of 400 mg as an intravenous infusion every 6 weeks. In certain aspects, said administration is a flat dose of 400 mg and occurs every 6 weeks until disease progression or unacceptable toxicity. In certain aspects, the immune checkpoint inhibitor is pembrolizumab and is administered at 2 mg / kg (up to 200 mg) as an intravenous infusion every 3 weeks for pediatrics. In certain aspects, the dosage form and strength of pembrolizumab injections is of 100 mg / 4 mL (or 25 mg / mL) solution in a single-dose vial. In certain aspects, the therapeutic substance is pembrolizumab and is administered with a Q6W dosing regimen of 400 mg as the effective amount. In certain aspects, administration to said subject comprises at least three Q6W flat dosages of 400 mg. In certain aspects, petosemtamab is administered in an amount of 1100 mg once every two weeks and pembrolizumab is administered in an amount of 400 mg once every six weeks. In certain aspects, both said dosages are a flat dose. In certain aspects, the antibody (e.g. petosemtamab) is provided to a subject using a flat dosage of 1500 mg. A flat dosage offers several advantages over body- surface or weight dosing as it reduces preparation time and reduces potential dose calculation mistakes. In certain aspects, the antibody is provided at a dosage of at least 500 mg. In certain aspects, said dosage is between 1100 to 2000 mg. In certain aspects, said dosage is between 1100 to 1800 mg. As is understood by the skilled person, the dosage can be administered over time. In certain aspects, the antibody is administered once every 2 weeks. In particular, the flat dosages disclosed herein are suitable for use in adults and / or in subjects weighing at least 35 kg. In certain aspects, the subject is afflicted with head and neck cancer. In certain aspects, said antibody, or functional part thereof, comprises petosemtamab and administrated in an amount of 1100 mg as an intravenous infusion once every two weeks. In certain aspects, said dose is a flat dose of 1100 mg. The treatment method described herein is typically continued for as long as the clinician overseeing the patient's care deems the treatment method to be effective, i.e., that the patient is responding to treatment. Non-limiting parameters that indicate the treatment method is effective may include one or more of the following: decrease in tumor cells; inhibition of tumor cell proliferation; tumor cell elimination; progression-free survival; appropriate response by a suitable tumor marker (if applicable). Kit-of-parts, and combinations of therapeutic agents In certain aspects, the present disclosure also provides a kit-of-parts comprising an antibody, or functional part thereof, that has an EGFR binding arm and / or which is capable if activating the complement system, instructions for use of said antibody, or functional part thereof, and instructions for use of a cysteinyl- leukotriene type 1 (CysLT1) receptor antagonist Also, the present disclosure provides a combination of an antibody, or functional part thereof, that has an EGFR binding arm and / or which is capable if activating the complement system, and a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist for use in the treatment of cancer in a subject in need thereof. Also, the present disclosure provides a combination of a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist, instructions for use of said cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist in the treatment of cancer in a subject, as well as instructions for use in the treatment of said cancer in a subject of an antibody, or functional part thereof, that has an EGFR binding arm and / or which is capable if activating the complement system. Also, the present disclosure provides a combination of an antibody, or functional part thereof, that has an EGFR binding arm and / or which is capable if activating the complement system, instructions for use of said antibody, or functional part thereof, in the treatment of cancer in a subject, as well as instructions for use in the treatment of said cancer in a subject of a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist. In certain aspects, said cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist comprises or is zafirlukast, montelukast and pranlukast. In certain aspects, said kit-of-parts further comprises an immune checkpoint inhibitor or instructions for use of said immune checkpoint inhibitor. In certain aspects, the present disclosure provides a pharmaceutical composition comprising an antibody, or functional part thereof, that has an EGFR binding arm and / or which is capable if activating the complement system and instructions for use thereof with a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist in the treatment of said cancer. In certain aspects, the present disclosure provides a pharmaceutical composition for the treatment of a cancer, comprising an antibody, or functional part thereof, that has an EGFR binding arm and / or which is capable if activating the complement system and a pharmaceutical composition for the treatment of said cancer, comprising a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist. In certain aspects, the present disclosure provides a pharmaceutical composition for use in the treatment of cancer comprising an antibody, or functional part thereof, that has an EGFR binding arm and / or which is capable if activating the complement system, wherein the pharmaceutical composition is administered in combination with a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist. In certain aspects, the present disclosure relates to a pharmaceutical composition for the treatment of a cancer comprising an antibody, or functional part thereof, that has an EGFR binding arm and / or which is capable if activating the complement system, wherein a subject to be treated in the treatment is administered a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist prior to administration of said antibody. In certain aspects, the present disclosure relates to a pharmaceutical composition for the treatment of a cancer in a subject comprising a cysteinyl- leukotriene type 1 (CysLT1) receptor antagonist, wherein said subject to be treated is administered an antibody, or functional part thereof, that has an EGFR binding arm and / or which is capable if activating the complement system after administration of said cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist. In certain aspects, an antibody, or functional part thereof, that has an EGFR binding arm and / or which is capable if activating the complement system is formulated as a pharmaceutical composition. In certain aspects, said pharmaceutical composition comprises said antibody or functional part thereof, a buffer system comprising a histidine buffer and / or a citrate buffer; a sugar component; and a non- ionic surfactant. In certain aspects, said pharmaceutical composition comprises 20 mg / ml antibody, 5 mM Histidine pH 6.3, 290 mM Sucrose, 0.1% Tween® 80. In certain aspects, said pharmaceutical composition comprises 20 mg / ml antibody,10 mM Histidine pH 5.9, 280 mM Sucrose, 0.05% Tween® 80. In certain aspects, said pharmaceutical composition comprises 20 mg / ml antibody,10 mM Histidine pH 5.9, 280 mM Sucrose, 0.1% Tween® 80. In certain aspects, said pharmaceutical composition comprises 20 mg / ml antibody,10 mM Na-Citrate pH 7.0, 280 mM Sucrose, 0.05% Tween® 80. In certain aspects, said pharmaceutical composition comprises petosemtamab. The present disclosure thus relates to a combination of medicaments for the treatment of cancer in a subject which comprises administration to said subject of multiple, different medicaments for treating said cancer, which treatment comprises simultaneous, sequential or separate administration of said medicaments. In certain aspects, said medicament comprises an antibody, or functional part thereof, that has an EGFR binding arm and / or which is capable if activating the complement system, and said other, different medicament comprises a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist. In certain aspects, a kit-of-parts or a combination comprises instructions for dosing of petosemtamab at 1500 mg. In certain aspects, said kit comprise instructions for use of petosemtamab for dosing at 1500 mg once every two weeks. In certain aspects, said kit comprises instructions for use of petosemtamab and an immune checkpoint inhibitor, such as pembrolizumab, in the treatment of head and neck cancer. In certain aspects, said kit comprise said kit comprises instructions for use of petosemtamab and said immune checkpoint inhibitor in the treatment of head and neck squamous cell cancer. In certain aspects, said kit comprises instructions for use of petosemtamab and pembrolizumab. In certain aspects, said kit comprises instructions for use of petosemtamab and pembrolizumab as mentioned herein, such a 400 mg, Q6W for pembrolizumab and 1500 mg, Q2W, of petosemtamab. In certain aspects, said kit comprises instructions for flat dosing of petosemtamab and flat dosing of pembrolizumab. In certain aspects, the present disclosure also provides a combination of an antibody, or functional part thereof, and a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist for use in the treatment of a cancer in a subject in need thereof. In certain aspects, the present disclosure also provides a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist for the treatment of a cancer in a subject in need thereof, wherein the cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist is for sequential administration with an antibody, or functional part thereof. In certain aspects, the cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist is administered prior to said antibody. In certain aspects, said antibody, or functional part thereof, is administered to a subject having cancer, to which said cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist has been administered or will be administered. Immune checkpoint inhibitors In certain aspects, the present disclosure relates to a combination therapy wherein an antibody that binds EGFR and / or which is capable of activating complement, is administered with an immune checkpoint inhibitor. In certain aspects, said immune checkpoint inhibitor comprises a PD-1 inhibitor. In certain aspects, the immune checkpoint inhibitor comprises or is an antibody. In certain aspects, the immune checkpoint inhibitor comprises or is an antibody that targets PD-1. In certain aspects, the immune checkpoint inhibitor comprises or is an antibody that inhibits PD-1. In certain aspects, the immune checkpoint inhibitor comprises or is an anti-PD- 1 antibody. In certain aspects, the immune checkpoint inhibitor is an antibody that binds or can bind PD-1. In certain aspects, the immune checkpoint inhibitor comprises or is pembrolizumab. Immune checkpoint inhibitors, such as PD-1 inhibitors, are known in the art. They include antibodies that bind and block PD-1. Pembrolizumab, for instance, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin’s lymphoma, stomach cancer, and cervical cancer. It is given by slow injection into a vein. Pembrolizumab is an antibody that binds to and blocks PD-1 located on lymphocytes. This receptor is a so-called "immune checkpoint”, and thus is generally responsible for preventing the immune system from attacking the body's own tissues. Normally, the PD-1 receptor on activated T-cells binds to the PD-L1 or PD-L2 ligands present on normal cells in the body, deactivating any potential cell-mediated immune response against these cells. Many cancers make proteins such as PD-L1 that also bind to the PD-1 receptor, thus shutting down the ability of the body to kill the cancer. Pembrolizumab works by inhibiting lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response. This allows the immune system to target and destroy cancer cells, but also blocks a key mechanism preventing the immune system from attacking the body itself. Pembrolizumab was approved for medical use in the United States in 2014. In 2017, the US Food and Drug Administration (FDA) approved it for any unresectable or metastatic solid tumor with certain genetic anomalies (mismatch repair deficiency or microsatellite instability). Pembrolizumab (sold under the brand name Keytruda™), is a humanized antibody used in cancer immunotherapy to treat a variety of cancers, including melanoma, lung cancer and Hodgkin lymphoma and functions as an immune checkpoint inhibitor. It is an IgG4 isotype antibody and targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes. Pembrolizumab was approved for medical use in the United States in 2014. In 2017, the US Food and Drug Administration (FDA) approved it for any unresectable or metastatic solid tumor with certain genetic anomalies. It is on the World Health Organization's List of Essential Medicines. The amino acid sequences of pembrolizumab is well known in the art. In certain aspects, the immune checkpoint inhibitor is, or comprises, Pembrolizumab or a functional fragment or variant thereof. In certain aspects, the immune checkpoint inhibitor comprises or consists of an amino acid sequence that is or has substantial sequence identity to the amino acid sequence of the antigen binding site of pembrolizumab. In certain aspects, the immune checkpoint inhibitor comprises heavy chain CDR1, CDR2 and CDR3 that are identical to CDR1, CDR2 and CDR3 from pembrolizumab. In certain aspects, the immune checkpoint inhibitor comprises light chain CDR1, light chain CDR2 and light chain CDR3 that are identical to CDR1, CDR2 and CDR3 from pembrolizumab. In certain aspects, the immune checkpoint inhibitor comprises the heavy chain and light chain sequences that are identical to said sequences from pembrolizumab. In certain aspects, the immune checkpoint inhibitor is administered pursuant to the present recommendation set by FDA approval. Said recommendations are typically comprised by instructions for use of in the treatment of cancer in a subject. Therefore, in certain aspects, the present disclosure relates to instructions for use of said immune checkpoint inhibitor. In certain aspects, the immune checkpoint inhibitor is, or comprises, pembrolizumab and is used in a combination therapy with petosemtamab. In certain aspects, said combination therapy further comprises the administration of a cysteinyl- leukotriene type 1 (CysLT1) receptor antagonist, in particular montelukast. All documents and references, including Genbank entries, patents and published patent applications, and websites, described herein are each expressly incorporated herein by reference to the same extent as if were written in this document in full or in part. For the purpose of clarity and a concise description features are described herein as part of the same or separate parts of the disclosure, however, it will be appreciated that the scope of the invention may include preferred aspects having combinations of all or some of the features described. The invention is now described by reference to the following examples, which are illustrative only, and are not intended to limit the present invention. While the invention has been described in detail and with reference to specific aspects thereof, it will be apparent to one of skill in the art that various changes and modifications can be made thereto without departing from the spirit and scope thereof.

[0002] List of clauses Clauses 1. An antibody, functional part, derivative and / or analogue thereof, comprising an EGFR binding arm for use in treating cancer, by intravenously infusing a prescribed dose of the antibody comprising - a first infused amount of the antibody over a first infusion period using a first infusion rate, - a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate. 2. An antibody, functional part, derivative and / or analogue thereof, comprising an EGFR binding arm for use in preventing or mitigating infusion-related reactions from intravenously infusing the antibody, comprising intravenously infusing a prescribed dose of the antibody using - a first infused amount of the antibody over a first infusion period using a first infusion rate, - a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate. 3. A method of intravenously infusing a prescribed dose of an antibody, functional part, derivative and / or analogue thereof, comprising an EGFR binding arm comprising intravenously infusing - a first infused amount of the antibody over a first infusion period using a first infusion rate, - a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate. 4. A method of mitigating or preventing the occurrence of infusion-related reactions from intravenous infusion of an antibody, functional part, derivative and / or analogue thereof, comprising an EGFR binding arm by intravenously infusing a prescribed dose of the antibody comprising - a first infused amount of the antibody over a first infusion period using a first infusion rate, - a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate. 5. A method of treating a subject suffering from cancer with a (prescribed) dose of an antibody, functional part, derivative and / or analogue thereof, comprising an EGFR binding arm comprising intravenously infusing - a first infused amount of the antibody over a first infusion period using a first infusion rate, - a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate. 6. An antibody, functional part, derivative and / or analogue thereof, capable of activating the complement system for use in treating cancer, by intravenously infusing a prescribed dose of the antibody comprising - a first infused amount of the antibody over a first infusion period using a first infusion rate, - a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate. 7. An antibody, functional part, derivative and / or analogue thereof, capable of activating the complement system for use in preventing or mitigating infusion-related reactions from intravenously infusing the antibody, comprising intravenously infusing a prescribed dose of the antibody using - a first infused amount of the antibody over a first infusion period using a first infusion rate, - a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate. 8. A method of intravenously infusing a prescribed dose of an antibody, functional part, derivative and / or analogue thereof, capable of activating the complement system comprising intravenously infusing - a first infused amount of the antibody over a first infusion period using a first infusion rate, - a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate. 9. A method of mitigating or preventing the occurrence of infusion-related reactions from intravenous infusion of an antibody, functional part, derivative and / or analogue thereof, capable of activating the complement system by intravenously infusing a prescribed dose of the antibody comprising - a first infused amount of the antibody over a first infusion period using a first infusion rate, - a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate. 10. A method of treating a subject suffering from cancer with a prescribed dose of an antibody, functional part, derivative and / or analogue thereof, capable of activating the complement system comprising intravenously infusing - a first infused amount of the antibody over a first infusion period using a first infusion rate, - a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate. 11. The use or method of any one of the preceding claims, wherein said use comprises providing a subject with a prescribed dose of said antibody. 12. The use or method of any one of the preceding clauses, wherein the second infusion period is longer than or equal to the first infusion period. 13. The use or method of any one of the preceding clauses, wherein the second infused amount of antibody is higher than the first infused amount. 14. The use or method of any one of the preceding clauses, further comprising infusing a third infused amount of the antibody over a third infusion period using a third infusion rate, wherein the third infused amount is higher than the second infused amount. 15. The use or method of claim 14, wherein the third infusion period is longer than or equal to the second infusion period. 16. The use or method of claim 14 or 15, wherein the third infusion rate is higher than the second infusion rate. 17. The use or method of any one of the preceding claims, further comprising infusing a fourth infused amount of the antibody over a fourth infusion period using a fourth infusion rate, wherein the fourth infused amount is higher than the third infused amount. 18. The use or method of clause 17, wherein the fourth infusion period is longer than or equal to the third infusion period. 19. The use or method of clause 17 or 18, wherein the fourth infusion rate is higher than the third infusion rate. 20. The use or method of any one of the preceding clauses, further comprising infusing a fifth infused amount of the antibody over a fifth infusion period using a fifth infusion rate, wherein the fifth infused amount is higher than the fourth infused amount. 21. The use or method of clause 20, wherein the fifth infusion period is longer than or equal to the fourth infusion period. 22. The use or method of clause 20 or 21, wherein the fifth infusion rate is higher than the fourth infusion rate. 23. The use or method of any one of the preceding clauses, wherein the EGFR binding arm is a variable domain that binds EGFR. 24. The use or method of any one of the preceding clauses, wherein the EGFR binding arm is a heavy chain variable domain that binds EGFR. 25. The use or method of any one the preceding clauses, wherein the EGFR binding arm comprises a variable domain that binds an extracellular domain of EGFR. 26. The use or method of any one the preceding clauses, wherein the EGFR binding arm consists of an antigen binding site that binds an extracellular part of EGFR. 27. The use or method of any one the preceding clauses, wherein the EGFR binding arm comprises a variable domain a heavy chain variable region that comprises at least the CDR1, CDR2 and CDR3 sequences of MF3755, MF8233, MF3370 and MF8232. 28. The use or method of any one the preceding clauses, wherein the EGFR binding arm comprises a variable domain with a heavy chain variable region thatcomprises the sequence of a VH chain of MF3755, MF8233, MF3370 and MF8232. 29. The use or method of any one of the preceding claims, wherein at least 400, at least 800, or at least 1000 mg of said antibody is administered on a single day. 30. The use or method of any one of the preceding clauses, wherein infusion of the prescribed dose of the antibody is completed on a single day. 31. The use or method of any one of the preceding claims, wherein infusion of the prescribed dose of the antibody occurs within 12 hours, within 8 hours, within 6 hours, within 4 hours, within 2 hours or within 1 hour. 32. The use or method of any one of the preceding clauses, wherein the first infused amount comprises about 0.5 to about 4 wt% (w / w) of the total amount of the antibody of the prescribed dose, from 1 to about 2 wt% (w / w), about 1 wt% (w / w) or about 2 wt% (w / w) of the prescribed dose. 33. The use or method of any one of the preceding clauses, wherein the first infusion period is from about 15 to about 75 minutes, from about 30 to about 60 minutes, about 30 minutes or is about 60 minutes. 34. The use or method of any one of the preceding clauses, wherein the first infused amount comprises from about 5 to about 50 mg antibody, from about 15 to about 30 mg antibody, about 15 or about 30 mg antibody. 35. The use or method of any one of the preceding clauses, wherein the first infusion rate is from about 20 to about 40 mg antibody per hour, or about 30 mg antibody per hour. 36. The use or method of any one of the preceding claims, wherein the first infusion rate is less than 50 mg antibody per hour. 37. The use or method of any one of the preceding clauses, wherein the second infused amount comprises from about 96 to about 99.5 wt% of the prescribed dose, or about 98 wt% of the prescribed dose. 38. The use or method of clause 37, wherein the second infusion period is from about 200 to about 300 minutes, from about 250 to about 260 minutes, or about 245 minutes. 39. The use or method of clause 37 or 38, wherein the second infused amount comprises about 1450 to about 1495 mg, about 1470 mg of the antibody or the remainder of the prescribed dose of the antibody. 40. The use or method of any one of clauses 37-38, wherein the second infusion rate is from about 300 to about 400 mg antibody per hour, or from about 360 to about 370 mg antibody per hour. 41. The use or method of any one of clauses 1-36, wherein the second infused amount comprises about 0.5 to about 4 wt% (w / w) of the total amount of the antibody of the prescribed dose, about 0.5 to about 2 wt% (w / w), or about 2 wt% (w / w). 42. The use or method of any one of clauses 1-36 or 41, wherein the second infusion period is from about 15 to about 45 minutes or about 30 minutes. 43. The use or method of any one of clauses 1-36 or 41-42, wherein the second infused amount comprises from about 20 to about 40 mg antibody, or about 30 mg antibody. 44. The use or method of any one of clauses 1-36 or 41-43, wherein the second infusion rate is from about 20 to about 40 mg antibody per hour, or about 30 mg antibody per hour. 45. The use or method of any one of clauses 1-36 or 41-44, wherein the third infused amount comprises about 2 to about 6 wt% (w / w) of the total amount of the prescribed dose or comprises about 4 wt% (w / w) of the total amount of the prescribed dose. 46. The use or method of any one of clauses 1-36 or 41-45, wherein the third infused amount is administered over a period of about 15 to about 45 minutes, or a period of about 30 minutes. 47. The use or method of any one of clauses 1-36 or 41-46, wherein the third infused amount comprises from about 40 to about 80 mg antibody, or about 60 mg antibody. 48. The use or method of any one of clauses 1-36 or 41-47, wherein the third infusion rate is from about 100 to about 140 mg antibody per hour, or about 120 mg antibody per hour. 49. The use or method of any one of clauses 1-36 or 41-48, wherein the fourth infused amount comprises about 6 to about 20 wt% (w / w) of the total amount of the prescribed dose or comprises about 8 or about 16 wt% (w / w) of the total amount of the prescribed dose. 50. The use or method of any one of clauses 1-36 or 41-49, wherein the fourth infused amount is administered over a period of about 15 to about 75 minutes, about 30 minutes or about 60 minutes. 51. The use or method of any one of clauses 1-36 or 41-50, wherein the fourth infused amount comprises from about 100 to about 300 mg antibody, about 120 mg or about 240 mg antibody. 52. The use or method of any one of clauses 1-36 or 41-51, wherein the fourth infusion rate is from about 200 to about 300 mg antibody per hour, or about 240 mg antibody per hour. 53. The use or method of any one of clauses 1-36 or 41-52, wherein the fifth infused amount provides about 68 to about 91 wt% (w / w) of the prescribed dose, about 77 or about 85 wt% (w / w) of the prescribed dose. 54. The use or method of any one of clauses 1-36 or 41-53, wherein the fifth infused amount is administered over a period of about 120 to about 240 minutes, about 158-162 minutes or about 190-196 minutes. 55. The use or method of any one of clauses 1-36 or 41-54, wherein the fifth infused amount comprises about 1100 to 1300 mg of the antibody, about 1150 to about 1160 mg, about 1270 to about 1280 mg or the remainder of the prescribed dose of the antibody. 56. The use or method of any one of clauses 1-36 or 41-55, wherein the fifth infusion rate is from about 300 to about 600 mg antibody per hour, about 340 to about 380 mg antibody per hour or about 450 to about 500 mg antibody per hour, or about 360 mg antibody per hour or about 480 mg antibody per hour. 57. The use or method of any one of the preceding clauses, wherein prior to the first infused amount of antibody, the subject is administered an effective dose of a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist, including zafirlukast, montelukast and pranlukast. 58. The use or method of clause 57, wherein the CysLT1 receptor antagonist is montelukast and administration thereof is about 48 hours, about 24 hours and / or about 1 hour, prior to infusion of the first infused amount of the antibody. 59. The use or method of clause 57 or 58, wherein an amount of about 5 to about 15 mg montelukast is administered. 60. The use or method of any one of clause 57-59, wherein an amount of about 10 mg montelukast is administered. 61. The use or method of any one of clause 57-60, wherein montelukast is orally administered. 62. The use or method of any one of the preceding clauses, wherein the intravenous infusion of the first infused amount of the antibody comprises a first exposure of the antibody to the subject. 63. The use or method of any one of the preceding clauses, wherein the use or method reduces the incidence and / or severity of infusion related reactions. 64. The use or method of any one of the preceding clauses, wherein the use or method reduces the incidence and / or severity of infusion related reactions of any one of grade 1, 2, 3 or 4. 65. The use or method of any one of the preceding clauses, wherein the use or method reduces the incidence and / or severity of infusion related reactions of grade 3 or 4. 66. The use or method of any one of the preceding clauses, wherein the use or method reduces the incidence and / or severity of the sum of grades 1-4 infusion related reactions, or the sum of grade 3 and 4 infusion related reactions. 67. The use or method of any one of the preceding clauses, wherein the use or method reduces the time for a subject to experience an infusion-related reaction. 68. The use or method of any one of the preceding clauses, wherein the cancer is an adenocarcinoma, a squamous cell carcinoma. 69. The use or method of any one of the preceding clauses, wherein the cancer is a head and neck cancer, including squamous cell carcinoma of the head and neck (SCCHN). 70. The use or method of any one of the preceding clauses, wherein the cancer is a cancer of the pharynx (including nasopharynx, oropharynx and hypopharynx), oral cavity, larynx, paranasal sinuses, nasal cavity or salivary glands. 71. The use or method of any one of the preceding clauses, wherein the cancer is colorectal cancer, pancreatic cancer, lung cancer, breast cancer, liver cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, melanoma, testis cancer, urothelial cancer, renal cancer, stomach cancer, carcinoid cancer, gastric cancer, esophageal cancer, gastric-esophageal-junction cancer or a brain glioma. 72. The use or method of any one of the preceding clauses, wherein the subject is a human subject. 73. The use or method of any one of the preceding clauses, wherein the antibody comprises an LGR5 binding arm, such as a variable domain that binds LGR5. 74. The use or method of any one the preceding clauses, wherein the EGFR binding arm comprises a variable domain a heavy chain variable region that comprises at least the CDR1, CDR2 and CDR3 sequences of MF5816. 75. The use or method of any one the preceding clauses, wherein the EGFR binding arm comprises a variable domain with a heavy chain variable region that comprises the sequence of the VH chain of MF5816. 76. The use or method of any one of the preceding clauses, wherein the antibody is ADCC enhanced. 77. The use or method of any one of the preceding clauses, wherein the antibody is afucosylated. 78. The use or method of any one of the preceding clauses, wherein the cancer is recurrent, unresectable, locally advanced and / or metastatic cancer. 79. The use or method of any one of the preceding clauses, wherein the antibody is petosemtamab. 80. The use or method of any one of the preceding clauses, wherein the prescribed dose of petosemtamab is 1100 mg. 81. The use or method of any one of the preceding clauses, wherein the prescribed dose of petosemtamab is 1500 mg. 82. The use or method of any one of the preceding clauses, wherein infusion of the initial dose is according to table 3. 83. The use or method of any one of the preceding clauses, wherein infusion of the initial dose is according to table 5. 84. The use or method of any one of the preceding clauses, wherein infusion of the initial dose is according to table 7. 85. The use or method of any one of the preceding clauses, wherein infusion of the initial dose is according to table 9. 86. The antibody for use or method of any one of the preceding clauses, wherein the antibody is formulated in a buffer system comprising a histidine buffer and / or a citrate buffer; a sugar component; and a non-ionic surfactant. 87. The antibody for use or method of any one of the preceding clauses, wherein the antibody is formulated in a concentration of 20 mg / ml in a solution comprising 5 mM histidine pH 6.3, 290 mM sucrose, 0.1% tween® 80; or 10 mM histidine pH 5.9, 280 mM sucrose, 0.05% tween® 80; or 10 mM histidine pH 5.9, 280 mM sucrose, 0.1% tween® 80 or 10 mM Na-citrate pH 7.0, 280 mM sucrose, 0.05% tween® 80. 88. The use or method of any one of the preceding clauses, wherein the antibody is cetuximab. 89. The use or method of any one of the preceding clauses, wherein the prescribed dose of cetuximab is 400 mg / m2body surface area. 90. The use or method of any one of the preceding clauses, wherein the antibody comprises a cMET binding arm, such as a variable domain that binds cMET. 91. The use or method of any one the preceding clauses, wherein the cMET binding arm comprises a variable domain a heavy chain variable region that comprises at least the CDR1, CDR2 and CDR3 sequences of MF8230 or MF4356. 92. The use or method of any one the preceding clauses, wherein the cMET binding arm comprises a variable domain with a heavy chain variable region that comprises the sequence of the VH chain of MF8230 or MF4356. 93. The use or method of any one the preceding clauses, wherein the EGFR, LGR5 and / or cMET binding arms comprises a light chain variable region that comprises at least the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 39. 94. The use or method of any one the preceding clauses, wherein the EGFR, LGR5 and / or cMET binding arms comprises a light chain variable region that comprises at least the sequence of SEQ ID NO: 39. 95. The use or method of any one of the preceding clauses, wherein the antibody is amivantamab. 96. The use or method of any one of the preceding clauses, wherein the prescribed dose of amivantamab is 1050 mg for a subject having a body weight of less than 80 kg or 1400 mg for a subject having a body weight of equal to or more than 80 kg. 97. The use or method of any one of the preceding clauses, wherein the antibody is any one of rituximab, ofatumumab, daratumumab, alemtuzumab, aducanumab, necitumumab, nimotuzumab, bicara, MEHD7945A, LY3164530, and AFM24. 98. An antibody comprising an EGFR binding arm for use in treating cancer, wherein the antibody is petosemtamab, comprising intravenously infusing said antibody at a rate of 30 mg / h for 30 minutes to infuse 15 mg of said antibody, followed by intravenously infusing said antibody at a rate of 60 mg / h for 30 minutes to infuse 30 mg of said antibody, followed by intravenously infusing said antibody at a rate of 120 mg / h for 30 minutes to infuse 60 mg of said antibody, followed by intravenously infusing said antibody at a rate of 240 mg / h for 60 minutes to infuse 240 mg of said antibody, followed by intravenously infusing said antibody at a rate of 360 mg / h for 192.5 minutes to infuse 1155 mg of said antibody, wherein 48 hours prior to the start of intravenously infusing said 15 mg of said antibody, said subject is orally administered 10 mg montelukast, wherein 24 hours prior to the start of intravenously infusing said 15 mg of said antibody, said subject is orally administered 10 mg montelukast and wherein one hour prior to the start of intravenously infusing said 15 mg of said antibody, said subject is orally administered 10 mg montelukast. 99. An antibody comprising an EGFR binding arm for use in treating cancer, wherein the antibody is petosemtamab, comprising intravenously infusing said antibody at a rate of 30 mg / h for 30 minutes to infuse 15 mg of said antibody, followed by intravenously infusing said antibody at a rate of 60 mg / h for 30 minutes to infuse 30 mg of said antibody, followed by intravenously infusing said antibody at a rate of 120 mg / h for 30 minutes to infuse 60 mg of said antibody, followed by intravenously infusing said antibody at a rate of 240 mg / h for 60 minutes to infuse 240 mg of said antibody, followed by intravenously infusing said antibody at a rate of 360 mg / h for about 125.8 minutes to infuse 755 mg of said antibody, wherein 48 hours prior to the start of intravenously infusing said 15 mg of said antibody, said subject is orally administered 10 mg montelukast, wherein 24 hours prior to the start of intravenously infusing said 15 mg of said antibody, said subject is orally administered 10 mg montelukast and wherein one hour prior to the start of intravenously infusing said 15 mg of said antibody, said subject is orally administered 10 mg montelukast. 100. The use or method of clause 98 or 99, wherein 24 hours prior to the start of intravenously infusing said 15 mg of said antibody, said subject is orally administered 8 mg of dexamethasone, and one hour before the start of the infusion, said subject is administered: dexamethasone 20 mg IV; and either one of dexchlorpheniramine 5 mg IV, diphenhydramine 50 mg PO or chlorpheniramine 10 mg IV; and either one of ranitidine 50 mg IV or 150 mg PO; and paracetamol 1 g IV or 650 mg PO. 101. The use or method of clause 98 or 99, wherein 24 hours prior to the start of intravenously infusing said 15 mg of said antibody, said subject is orally administered 8 mg of dexamethasone, and one hour before the start of the infusion, said subject is administered: dexamethasone 20 mg IV; and either one of dexchlorpheniramine 10 mg IV, diphenhydramine 50 mg PO or chlorpheniramine 20 mg IV; and either one of ranitidine 50 mg IV, 150 mg PO or famotidine 20 mg IV; and paracetamol 1 g IV or 650 mg PO. 102. The use or method of any one of the preceding clauses, wherein said infusion- related reactions comprise Grade 1 infusion-related reactions. 103. The use or method of any one of the preceding clauses, wherein said infusion- related reactions comprise Grade 2 infusion-related reactions. 104. The use or method of any one of the preceding clauses, wherein said infusion- related reactions comprise Grade 3 infusion-related reactions. 105. The use or method of any one of the preceding clauses, wherein said infusion- related reactions comprise Grade 4 infusion-related reactions. 106. The use or method of any one of the preceding clauses, wherein a dosing and premedication regimen according to Example 4 is used before infusing a subject. 107. The use or method of any one of the preceding clauses, wherein a dosing regimen according to Table 3 is used while infusing a subject. 108. The use or method of any one of the preceding clauses, wherein a dosing and premedication regimen according to Example 5 is used before infusing a subject. 109. The use or method of any one of the preceding clauses, wherein a dosing regimen according to Table 5 is used while infusing a subject. 110. The use or method of any one of the preceding clauses, wherein a dosing and premedication regimen according to Example 6 is used before infusing a subject. 111. The use or method of any one of the preceding clauses, wherein a dosing regimen according to Table 7 is used while infusing a subject. 112. The use or method of any one of the preceding clauses, wherein a dosing and premedication regimen according to Example 7 is used before infusing a subject. 113. The use or method of any one of the preceding clauses, wherein a dosing regimen according to Table 9 is used while infusing a subject. 114. The use or method of any one of the preceding clauses, wherein a dosing and premedication regimen according to Example 8 is used before infusing a subject. 115. The use or method of any one of the preceding clauses, wherein a dosing regimen according to Table 10 is used while infusing a subject. 116. The use or method of any one of the preceding clauses, wherein said first infusion period is followed by said second infusion period, and optionally said second infusion period is followed by a third infusion period, and optionally said third infusion period is followed by a fourth infusion period, and optionally said fourth infusion period is followed by a fifth infusion period. 117. The use or method of any one of the preceding clauses, wherein the combined infusion periods are at least 250 minutes. 118. The use or method of any one of the preceding clauses, wherein said use or method further comprises administration of a second therapeutic, such as an antibody. 119. The use or method of any one of the preceding clauses, wherein said use or method further comprises administration of pembrolizumab as a second therapeutic. 120. The use or method of any one of the preceding clauses, wherein said use or method further comprises administration of pembrolizumab as a second therapeutic which is administered on the same day as said antibody comprising an EGFR binding arm. 121. The use or method of any one of the preceding clauses, wherein said use or method further comprises subcutaneous administration of pembrolizumab as a second therapeutic. 122. The use or method of any one of the preceding clauses, wherein said use or method further comprises intravenous administration of pembrolizumab as a second therapeutic. EXAMPLES Example 1. Clinical trial protocol using petosemtamab monotherapy Petosemtamab administration Petosemtamab is administered by IV infusion Q2W, with a flat dose of 750, 1100 or 1500 mg. The administered dose, dose increments, and frequency of dosing for each patient and each cohort is subject to change based on patient safety, PK and PD data. 1500 mg Q2W is used. Infusions are administered IV over approximately 6 h for the Cycle 1 Day 1 infusion. Subsequent infusions after Cycle 1 Day 1 can be reduced to 2 h (±15 min) at the investigator’s discretion and in the absence of IRRs. A cycle is considered 4 weeks. For each patient, a 1 h observation period will be implemented following the end of infusion (EOI). As the escalation phase of the study is finished, 3 dose levels have reached full receptor occupancy levels in >90% of analyzed time points (i.e., 750, 1100, and 1500 mg) with petosemtamab given Q2W. Treatment Schedule Petosemtamab is administered as a 2 to 6 h IV infusion Q2W, with 4-week cycles (i.e. starting at C1D1, C1D15, C2D1, C2D15 etc.). Details of petosemtamab administration over the approximate 6 h infusion as well as details on premedication are provided in the following Examples. Day 1 of the subsequent cycle will be on Day 29 or after recovery from any AEs associated with the previous cycle. Petosemtamab is intravenously infused using a concentration of 3 mg / ml antibody, after diluting from a stock concentration of 20 mg / ml using a pharmaceutically suitable diluent. During Cycle 1 Day 1, all infusions are administered over a period of approximately 6 h after receiving a premedication regimen. If a patient tolerates Cycle 1 Day 1 petosemtamab infusion with no severe IRRs and the investigator considers it appropriate, then the patient can continue receiving further petosemtamab infusions and follow a simplified premedication regimen; the duration of infusions can then be reduced to 2 h. In such cases, the infusion duration may be extended back up to approximately 4 h when considered appropriate to avoid or reduce the incidence or severity of IRRs. After Cycle 1 Day 1, patients will be observed for 1 h after EOI. Example 2. Clinical trial protocol using petosemtamab in combination with pembrolizumab Petosemtamab administration The clinical trial protocol using a combination of petosemtamab in combination with pembrolizumab follows Example 1, with the following adaptations. Pembrolizumab administration Pembrolizumab is 400 mg Q6W and is administered through 30-minute IV infusion and / or following the label instructions in each country. Treatment Schedule Pembrolizumab is infused initially at a flat dose of 400 mg IV (30-minute infusion, and / or following the label instructions in each country) on Cycle 1 Day 1 and then continue at a flat dose of 400 mg Q6W. Pembrolizumab should be administered immediately after petosemtamab end of administration as long as any reaction to petosemtamab is completely resolved. If pembrolizumab is given on the same day as petosemtamab, then pembrolizumab is administered after infusion of petosemtamab. Pembrolizumab treatment is given until disease progression, intolerable toxicity, or up to 24 months. Beyond 24 months, patients may continue receiving petosemtamab alone if no PD and they derive clinical benefit from the treatment. Example 3. Initial C1D1 dosing scheme Dosing of petosemtamab was conducted in a population of 40 patients suffering from colorectal, gastro-intestinal junction and head and neck cancer following the treatment schedule of Example 1 using the C1D1 dosing scheme as shown in Table 1 (data cut-off 06 November 2023). Steps Rate (mg / h) Duration (h) Amount dosed (mg) Step 1 375 4 1500 Table 1. IV infusion schemes use to administer 1500 mg petosemtamab using a concentration of 3 mg / ml antibody in a total volume of 500 ml. Paracetamol / acetaminophen, antihistamines and corticosteroids were administered according to standard local clinical practice with the C1D1 infusion. Intravenous infusion following the scheme of Table 1 led to the results as mentioned in Table 2. ≥ 1 IRR Grade 1 Grade 2 Grade 3 Grade 4 Median time-to- No. pts with at first-IRR (min) least one Grade 3 or 4 IRR 31 (77%) 9 (22%) 14 (35%) 4 (10%) 4 (10%) 15 8 (20%) Table 2: IRR incidence and severity at C1D1 following the dose instruction of Table 1. Also, following the dosing scheme of Table 1, in 30 patients (75%) IRR events were reported that caused treatment interruptions with a median duration of around 81 minutes, of which in 25 patients infusion could be restarted again on the same day. Permanent treatment discontinuation was reported from adverse events in 4 patients (10%). Example 4. C1D1 dosing scheme 1 Dosing of petosemtamab was conducted in a population of 24 patients suffering from head and neck cancer following the treatment schedule of Example 1, following the C1D1 dosing scheme V1 as shown in Table 3 (data cut-off 06 November 2023). Steps Rate (mg / h) Duration (mins) Amount dosed (mg) Step 1 30 60 30 Step 2 362.5 245 1470 Table 3. IV infusion scheme V1 used to administer 1500 mg petosemtamab. A premedication regimen including dexamethasone, antihistamines or paracetamol is included with infusions in Cycle 1, on Day 1, initiated 24 hours prior to each infusion. In more detail, 24 hours before the start of the infusion, 8 mg of dexamethasone PO is administered. Then, one hour before the start of the infusion, each patient received dexamethasone 20 mg IV; and dexchlorpheniramine 5 mg IV, diphenhydramine 50 mg PO or chlorpheniramine 10 mg IV; and ranitidine 50 mg IV or 150 mg PO; and paracetamol 1g IV or 650 mg PO. Intravenous infusion of the initial C1D1 dose following the scheme of Table 3 led to the results as mentioned in Table 4. ≥ 1 IRR Grade 1 Grade 2 Grade 3 Grade 4 Median time-to- No. pts with at first-IRR (min) least one Grade 3 or 4 IRR 16 (67%) 5 (21%) 6 (25%) 4 (17%) 1 (4%) 79 5 (21%) Table 4: IRR incidence and severity at C1D1 following the dose instruction of Table 3. Also, following the dosing scheme of Table 3, in 15 patients (62%) IRR events werereported that caused treatment interruptions with a median duration of around 37minutes, of which in 10 patients infusion could be restarted again on the same day. Permanent treatment discontinuation was reported from adverse events in 1 patient (4%). Example 5. C1D1 dosing scheme 2 Dosing of petosemtamab was conducted in a population of 14 patients, including those suffering from solid tumors including gastric or gastro-intestinal junction cancer, and head and neck cancer following the treatment schedule of Example 1, following the C1D1 dosing scheme V2 as shown in Table 5 (data cut-off 06 November 2023). Steps Rate (mg / h) Duration (mins) Amount dosed (mg) Step 1 30 30 15 Step 2 60 30 30 Step 3 120 30 60 Step 4 240 30 120 Step 5 480 About 160 1275 Table 5. IV infusion scheme V2 used to administer 1500 mg petosemtamab. The premedication regimen based on administration of dexamethasone, antihistamines and paracetamol as mentioned in Example 4 was included, but with dexchlorpheniramine administered at 10 mg IV, or chlorpheniramine administered at 20 mg IV. Furthermore, famotidine administered at 20 mg IV was added as an alternative to ranitidine and cimetidine. Intravenous infusion of the initial C1D1 dose following the scheme of Table 5 led to the results as mentioned in Table 6. ≥ 1 IRR Grade 1 Grade 2 Grade 3 Grade 4 Median time-to- No. pts with at first-IRR (min) least one Grade 3 or 4 IRR 9 (64%) 1 (7%) 5 (36%) 2 (14%) 1 (7%) 95 3 (21%) Table 6: IRR incidence and severity at C1D1 following the dose instruction of Table 5. Also, following the dosing scheme of Table 5, in 7 patients (50%) IRR events were reported that caused treatment interruptions with a median duration of around 53 minutes, of which in 5 patients infusion could be restarted again on the same day. Permanent treatment discontinuation was reported from adverse events in 1 patient (7%). A total of 3 patients were administered petosemtamab according to the C1D1 dosing scheme of Table 5 but with premedication according to Example 6 which includes montelukast. In these three patients, the median time-to-first-IRR was reported to be 82 minutes, one patient was reported having at least one IRR of Grade 3 or 4, one patient was reported to have an IRR of Grade 1 and one patient was reported to have an IRR of Grade 3. No permanent discontinuation for this group was reported. In one patient an infusion interruption was reported. Example 6. C1D1 dosing scheme 3 Dosing of petosemtamab was conducted in a population of 53 patients suffering from head and neck cancer, with 27 patients following the treatment schedule of Example 1 at 1500 mg of petosemtamab; 26 patients following the combination treatment of Example 2 at 1500 mg of petosemtamab, following the C1D1 dosing scheme V3 as shown in Table 7 (data cut-off 06 November 2023). Further dosing of petosemtamab was conducted in a population of 11 patients suffering from head and neck cancer following the treatment schedule of Example 1 at 1100 mg of petosemtamab following the C1D1 dosing scheme V3 in Table 9 (data cut- off 06 November 2023). Steps Rate (mg / h) Duration (mins) Amount dosed (mg) Step 1 30 30 15 Step 2 60 30 30 Step 3 120 30 60 Step 4 240 60 240 Step 5 360 192.5 1155 Table 7. IV infusion scheme V3 used to administer 1500 mg petosemtamab at 3 mg / ml in 500 ml total volume. The dosing scheme of Table 7 sets out an infusion rate in the first step of 10 mL / h, followed by 20, 40, 80 and 120 mL / h, respectively for steps 2-5. Corresponding infusion volumes for steps 1-5 are 5, 10, 20, 80 and 385 mL, respectively. The cumulative dosages for steps 1-5 are 15, 45, 105, 345 and 1500 mg petosemtamab. The premedication regimen based on administration of dexamethasone, antihistamines and paracetamol as mentioned in Example 3 was included. Premedication prior to infusion on C1D1 included the premedication regimen of Example 5 but with addition of montelukast as follows. 48 hours prior to start of infusion, montelukast is administered at 10 mg orally (PO). Within 24 hours prior to start of infusion, montelukast is administered at 10 mg PO. One hour prior to start of infusion, montelukast is administered at 10 mg PO. Intravenous infusion of the initial C1D1 dose following the scheme of Table 7 or Table 9 with addition of montelukast led to the results as mentioned in Table 8, which includes the IRR incidence and severity for 27 patients receiving 1500mg of petosemtamab noted above following Example 1; 11 patients receiving 1100mg of petosemtamab noted above following Example 1; and 26 receiving 1500mg of petosemtamab noted above following Example 2. ≥ 1 IRR Grade 1 Grade 2 Grade 3 Grade 4 Median time-to- No. pts with at first-IRR (min) least one Grade 3 or 4 IRR 16 (30%) 8 (15%) 7 (13%) 1 (2%) 0 (0%) 75 1 (2%) Table 8: IRR incidence and severity at C1D1 following the dose instruction of Table 7. Also, following the dosing scheme of Table 7, in 14 patients (26%) IRR events were reported that caused treatment interruptions with a median duration of around 47 minutes, of which in 13 patients infusion could be restarted again on the same day. Permanent treatment discontinuation from adverse events was not reported to have occurred in any patient. Aggregated data on from a July 2024 data cut-off is presented in Example 9, in particular in Table 11, which captures infusion-related reactions for 82 patients having been given 1500 mg petosemtamab monotherapy following Example 1. Example 7. C1D1 dosing scheme 4 When 1100 mg petosemtamab is to be dosed on the C1D1 time point following the treatment schedule of Example 1, the dosing scheme as shown in Table 9 is applicable. Steps Rate (mg / h) Duration (mins) Amount dosed (mg) Step 1 30 30 15 Step 2 60 30 30 Step 3 120 30 60 Step 4 240 60 240 Step 5 360 about 126 755 Table 9. IV infusion scheme used to administer 1100 mg petosemtamab. The premedication regimen based on administration of dexamethasone, antihistamines, paracetamol and montelukast as mentioned in Example 6 can be applied. Example 8. Premedication scheme and C1D1 dosing regimen Dosing of petosemtamab is conducted in this example following the treatment schedule of Example 1, premedication schedule of Table 10 and C1D1 dosing scheme V3 as shown in Table 7. Medicationd,eTypical premedication and Route of Recommended dosing its dosing per subject per administration window before indicated timing petosemtamab infusion Leukotriene Montelukast 10 mgOral ^ On Day 2,receptor antagonist (or equivalent)a^ On Day 1, and(Premedication for^ On the day of infusionC1D1 only) Glucocorticoid Dexamethasone 8-10 mgOral ^ On Day 1(or equivalent) Glucocorticoid Dexamethasone 20 mgIV ^ On the day of infusion(or equivalent) (recommended within 1 hour) H1 antihistamine Diphenhydramine 50 mg Oral or IV ^ On the day of infusion(or equivalent)b(recommended within 1 hour)H2 antihistamine Ranitidine 50 mg (or Oral or IV ^ On the day of infusionequivalent)c(recommended within 1 hour) Antipyretic ParacetamolOral or IV ^ On the day of infusion(acetaminophen) (recommended within 650 mg to 1000 mg (or 1 hour) equivalent) Table 10. C1D1 (Day 1 and optionally Day 15) petosemtamab premedication scheme.aMontelukast 10 mg is only included for C1D1 (Day 2, Day 1 and day of infusion) after which this premedication can be stopped.bDiphenhydramine may be substituted with dexchlorpheniramine 10 mg IV orchlorpheniramine 20 mg IV or equivalent.cRanitidine 50 mg may be substituted for ranitidine 50 mg IV with 150 mg PO, or famotidine 20 mg IV, or cimetidine 300 mg IV or equivalent. If not locally available or approved for use and a substitute is not available or approved for use, then medication can be omitted.dIf a medication noted in this table is not locally available, a similar medication and dose maybe substituted and administered per local guidelines.eParticipants for whom required medications are contraindicated, alternative medications may be considered. Example 9. Aggregated data on infusion-related reactions from administering at 1500 mg petosemtamab as monotherapy. Clinically-relevant data from a July 2024 data cut-off that includes data from Examples 3 through 6, capturing infusion-related reactions for 82 monotherapy patients given 1500 mg petosemtamab, is shown in Table 11. Preferred Term Prior administration regimen Administration regimen according according to example 3 (n=49) to Example 6 (n=33) At least one All grades, n (%) Grade 3–4, n All grades n (%) Grade 3–4, n TEAE of IRR (%) (%) IRR 12 (24) 7 (14) 7 (21) 2 (6) Hypotension 10 (20) 4 (8) 4 (12) 0 Flushing 8 (16) 2 (4) 2 (6) 1 (3) Nausea 6 (12) 0 2 (6) 0 Dyspnea 5 (10) 1 (2) 0 0 Erythema 5 (10) 0 0 0 Table 11. Infusion-related reactions for monotherapy patients given 1500 mg petosemtamab (data cut-off July 2024). Example 10. Infusion-related reactions reported for combination therapy comprising petosemtamab and pembrolizumab. Following Example 2, IRRs reported for the combination of 1500 mg petosemtamab Q2W and 400 mg pembrolizumab Q6W administered to patients suffering from HNSCC, are as follows. TEAEs were reported in 45 patients; most were Grade 1 or Grade 2. Grade ≥3 TEAEs occurred in 27 patients (60%), including 20 (44%) who experienced treatment-related TEAEs. No individual Grade ≥3 TEAE occurred in >7% of patients. No Grade 5 treatment-related TEAEs were reported. IRRs occurred in 38% of patients, with 7% Grade 3; without any Grade 4 or Grade 5; mainly occurred during first infusion and were resolved. No significant overlapping toxicities were observed (data cut-off 27thFeb 2025).

Claims

Claims 1. An antibody comprising an EGFR binding arm, and optionally an LGR5 binding arm, for use in treating cancer, comprising intravenously infusing - a first infused amount of the antibody over a first infusion period using a first infusion rate, - followed by a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate.

2. An antibody comprising an EGFR binding arm, and optionally an LGR5 binding arm, for use in treating cancer, comprising intravenously infusing - a first infused amount of the antibody over a first infusion period using a first infusion rate, - followed by a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate, wherein said intravenously infusing of said antibody over a first and second infusion period is for preventing or mitigating infusion-related reactions related to intravenously infusing said antibody.

3. A method of administering to a subject an antibody comprising an EGFR binding arm, and optionally an LGR5 binding arm, comprising intravenously infusing - a first infused amount of the antibody over a first infusion period using a first infusion rate, - followed by a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate.

4. A method of mitigating or preventing the occurrence of infusion-related reactions from intravenous infusion of an antibody comprising an EGFR binding arm, and optionally an LGR5 binding arm, comprising intravenously infusing - a first infused amount of the antibody over a first infusion period using a first infusion rate,- followed by a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate.

5. A method of treating a subject suffering from cancer with a dose of an antibody comprising an EGFR binding arm, and optionally an LGR5 binding arm, comprising intravenously infusing - a first infused amount of the antibody over a first infusion period using a first infusion rate, - followed by a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate.

6. The antibody for use or method of any one of the preceding claims, wherein said use comprises providing a subject with a prescribed dose of said antibody.

7. The antibody for use or method of any one of the preceding claims, wherein the second infusion period is longer than or equal to the first infusion period.

8. The antibody for use or method of any one of the preceding claims, wherein the second infused amount of antibody is higher than the first infused amount.

9. The antibody for use or method of any one of the preceding claims, further comprising infusing a third infused amount of the antibody over a third infusion period using a third infusion rate, wherein the third infused amount is higher than the second infused amount and wherein infusing said third infused amount follows infusion of said second infused amount.

10. The antibody for use or method of claim 9, wherein the third infusion period is longer than or equal to the second infusion period.

11. The antibody for use or method of claim 9 or 10, wherein the third infusion rate is higher than the second infusion rate.

12. The antibody for use or method of any one of the preceding claims, further comprising infusing a fourth infused amount of the antibody over a fourth infusion period using a fourth infusion rate, wherein the fourth infused amount is higher than the third infused amount and wherein infusing said fourth infused amount follows infusion of said third infused amount.

13. The antibody for use or method of claim 12, wherein the fourth infusion period is longer than or equal to the third infusion period.

14. The antibody for use or method of claim 12 or 13, wherein the fourth infusion rate is higher than the third infusion rate.

15. The antibody for use or method of any one of the preceding claims, further comprising infusing a fifth infused amount of the antibody over a fifth infusion period using a fifth infusion rate, wherein the fifth infused amount is higher than the fourth infused amount and wherein infusing said fifth infused amount follows infusion of said fourth infused amount.

16. The antibody for use or method of claim 15, wherein the fifth infusion period is longer than or equal to the fourth infusion period.

17. The antibody for use or method of claim 15 or 16, wherein the fifth infusion rate is higher than the fourth infusion rate.

18. The antibody for use or method of any one of the preceding claims, wherein the antibody is petosemtamab, cetuximab or amivantamab.

19. The antibody for use or method of any one of the preceding claims, wherein the antibody is petosemtamab.

20. The antibody for use or method of any one of the preceding claims, wherein at least 400, at least 800, or at least 1000 mg of said antibody is administered on a single day.

21. The antibody for use or method of any one of the preceding claims, wherein the prescribed dose of the antibody is 1100 or 1500 mg.

22. The antibody for use or method of any one of the preceding claims, wherein infusion of the prescribed dose of the antibody occurs on a single day.

23. The antibody for use or method of any one of the preceding claims, wherein infusion of the prescribed dose of the antibody occurs within 12 hours, within 8 hours, or within 6 hours.

24. The antibody for use or method of any one of the preceding claims, wherein the first infused amount comprises about 0.5 to about 4 wt% (w / w) of the total amount of the antibody of the prescribed dose, from 1 to about 2 wt% (w / w), about 1 wt% (w / w) or about 2 wt% (w / w) of the prescribed dose.

25. The antibody for use or method of any one of the preceding claims, wherein the first infusion period is from about 15 to about 75 minutes, from about 30 to about 60 minutes, about 30 minutes or is about 60 minutes.

26. The antibody for use or method of any one of the preceding claims, wherein the first infused amount comprises from about 5 to about 50 mg antibody, from about 15 to about 30 mg antibody, about 15 or about 30 mg antibody.

27. The antibody for use or method of any one of the preceding claims, wherein the first infusion rate is less than 50 mg antibody per hour.

28. The antibody for use or method of any one of the preceding claims, wherein the first infusion rate is from about 20 to about 40 mg antibody per hour, or about 30 mg antibody per hour.

29. The antibody for use or method of any one of the preceding claims, wherein the second infused amount comprises from about 96 to about 99.5 wt% of the prescribed dose, or about 98 wt% of the prescribed dose.

30. The antibody for use or method of claim 29, wherein the second infusion period is from about 200 to about 300 minutes, from about 250 to about 260 minutes, or about 245 minutes.

31. The antibody for use or method of claim 29 or 30, wherein the second infused amount comprises about 1450 to about 1495 mg, about 1470 mg of the antibody or the remainder of the prescribed dose of the antibody.

32. The antibody for use or method of any one of claims 29-31, wherein the second infusion rate is from about 300 to about 400 mg antibody per hour, or from about 360 to about 370 mg antibody per hour.

33. The antibody for use or method of any one of claims 1-28, wherein the second infused amount comprises about 0.5 to about 4 wt% (w / w) of the total amount of the antibody of the prescribed dose, about 0.5 to about 2 wt% (w / w), or about 2 wt% (w / w).

34. The antibody for use or method of any one of claims 1-28 or 33, wherein the second infusion period is from about 15 to about 45 minutes or about 30 minutes.

35. The antibody for use or method of any one of claims 1-28 or 33-34, wherein the second infused amount comprises from about 20 to about 40 mg antibody, or about 30 mg antibody.

36. The antibody for use or method of any one of claims 1-28 or 33-35, wherein the second infusion rate is from about 20 to about 40 mg antibody per hour, or about 30 mg antibody per hour.

37. The antibody for use or method of any one of claims 1-28 or 33-36, wherein the third infused amount comprises about 2 to about 6 wt% (w / w) of the total amount of the prescribed dose or comprises about 4 wt% (w / w) of the total amount of the prescribed dose.

38. The antibody for use or method of any one of claims 1-28 or 33-37, wherein the third infused amount is administered over a period of about 15 to about 45 minutes, or a period of about 30 minutes.

39. The antibody for use or method of any one of claims 1-28 or 33-38, wherein the third infused amount comprises from about 40 to about 80 mg antibody, or about 60 mg antibody.

40. The antibody for use or method of any one of claims 1-28 or 33-39, wherein the third infusion rate is from about 100 to about 140 mg antibody per hour, or about 120 mg antibody per hour.

41. The antibody for use or method of any one of claims 1-28 or 33-40, wherein the fourth infused amount comprises about 6 to about 20 wt% (w / w) of the total amount of the prescribed dose or comprises about 8 or about 16 wt% (w / w) of the total amount of the prescribed dose.

42. The antibody for use or method of any one of claims 1-28 or 33-41, wherein the fourth infused amount is administered over a period of about 15 to about 75 minutes, about 30 minutes or about 60 minutes.

43. The antibody for use or method of any one of claims 1-28 or 33-42, wherein the fourth infused amount comprises from about 100 to about 300 mg antibody, about 120 mg or about 240 mg antibody.

44. The antibody for use or method of any one of claims 1-28 or 33-43, wherein the fourth infusion rate is from about 200 to about 300 mg antibody per hour, or about 240 mg antibody per hour.

45. The antibody for use or method of any one of claims 1-28 or 33-44, wherein the fifth infused amount provides about 68 to about 91 wt% (w / w) of the prescribed dose, about 77 or about 85 wt% (w / w) of the prescribed dose.

46. The antibody for or method of any one of claims 1-28 or 33-45, wherein the fifth infused amount is administered over a period of about 120 to about 240 minutes, about 158-162 minutes or about 190-196 minutes.

47. The antibody for use or method of any one of claims 1-28 or 33-46, wherein the fifth infused amount comprises about 1100 to 1300 mg of the antibody, about 1150 to about 1160 mg, about 1270 to about 1280 mg or the remainder of the prescribed dose of the antibody.

48. The antibody for use or method of any one of claims 1-28 or 33-47, wherein the fifth infusion rate is from about 300 to about 600 mg antibody per hour, about 340 to about 380 mg antibody per hour or about 450 to about 500 mg antibody per hour, or about 480 mg antibody per hour.

49. The antibody for use or method of any one of the preceding claims, wherein prior to the first infused amount of antibody, the subject is administered an effective dose of a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist, including zafirlukast, montelukast and pranlukast.

50. The antibody for use or method of claim 49, wherein the CysLT1 receptor antagonist is montelukast and administration thereof is about 48 hours, about 24 hours and / or about 1 hour, prior to infusion of the first infused amount of the antibody.

51. The antibody for use or method of claim 49 or 50, wherein an amount of about 5 to about 15 mg montelukast is administered.

52. The antibody for use or method of any one of claim 49-51, wherein an amount of about 10 mg montelukast is administered.

53. The antibody for use or method of any one of claim 49-52, wherein montelukast is orally administered.

54. The antibody for use or method of any one of the preceding claims, wherein prior to the first infused amount of antibody, the subject is administered an effective dose of a compound comprising dexamethasone, dexchlorpheniramine, diphenhydramine, chlorpheniramine, ranitidine, famotidine, cimetidine and / or paracetamol.

55. The antibody for use or method of claim 54, wherein administration of said compound is within about 4, 2 or 1 hour, prior to infusion of the first infused amount of the antibody.

56. The antibody for use or method of claim 54 or 55, wherein an amount of about 20 mg IV dexamethasone, about 10 mg IV dexchlorpheniramine, about 50 mg PO diphenhydramine, about 20 mg IV chlorpheniramine, about 50 mg IV or about 150 mg PO ranitidine, about 20 mg IV famotidine, about 300 mg IV cimetidine, about 1 g PO or about 650 mg IV paracetamol is administered.

57. The antibody for use or method of any one of the preceding claims, wherein the infusion of the antibody comprises a first exposure of the antibody to the subject.

58. The antibody for use or method of any one of the preceding claims, wherein the use or method prolongs the time for a subject to experience an infusion-related response.

59. The antibody for use or method of any one of the preceding claims, wherein the cancer is an adenocarcinoma, a squamous cell carcinoma.

60. The antibody for use or method of any one of the preceding claims, wherein the cancer is a head and neck cancer, including squamous cell carcinoma of the head and neck (SCCHN).

61. The antibody for use or method of any one of the preceding claims, wherein the cancer is a cancer of the pharynx (including nasopharynx, oropharynx and hypopharynx), oral cavity, larynx, paranasal sinuses, nasal cavity or salivary glands.

62. The antibody for use or method of any one of the preceding claims, wherein the cancer is colorectal cancer, pancreatic cancer, lung cancer, breast cancer, liver cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, melanoma, testis cancer, urothelial cancer, renal cancer, stomach cancer, carcinoid cancer, gastric cancer, esophageal cancer, gastric-esophageal-junction cancer or a brain glioma.

63. The antibody for use or method of any one of the preceding claims, wherein the subject is a human subject.

64. The antibody for use or method of any one of the preceding claims, wherein the antibody comprises a variable domain that binds LGR5.

65. The antibody for use or method of any one of the preceding claims, wherein the antibody is formulated in a buffer system comprising a histidine buffer and / or a citrate buffer; a sugar component; and a non-ionic surfactant.

66. The antibody for use or method of any one of the preceding claims, wherein the antibody is formulated in a concentration of 20 mg / ml in a solution comprising 5 mM histidine pH 6.3, 290 mM sucrose, 0.1% tween®80; or 10 mM histidine pH 5.9, 280 mM sucrose, 0.05% tween®80; or 10 mM histidine pH 5.9, 280 mM sucrose, 0.1% tween®80 or 10 mM Na-citrate pH 7.0, 280 mM sucrose, 0.05% tween®80.

67. The antibody for use or method of any one of the preceding claims, wherein the cancer is recurrent, unresectable, locally advanced and / or metastatic cancer.

68. An antibody comprising an EGFR binding arm for use in treating cancer, wherein the antibody is petosemtamab, comprising intravenously infusing said antibody at a rate of 30 mg / h for 30 minutes to infuse 15 mg of said antibody, followed by intravenously infusing said antibody at a rate of 60 mg / h for 30 minutes to infuse 30 mg of said antibody, followed by intravenously infusing said antibody at a rate of 120 mg / h for 30 minutes to infuse 60 mg of said antibody, followed by intravenously infusing said antibody at a rate of 240 mg / h for 60 minutes to infuse 240 mg of said antibody, followed by intravenously infusing said antibody at a rate of 360 mg / h for192.5 minutes to infuse 1155 mg of said antibody, further comprising administration of montelukast at 48 hours prior to the start of intravenously infusing said 15 mg of said antibody, administration of montelukast at 24 hours prior to the start of intravenously infusing said 15 mg of said antibody and administration of montelukast at one hour prior to the start of intravenously infusing said 15 mg of said antibody.

69. An antibody capable of activating the complement system for use in treating cancer, by intravenously infusing a prescribed dose of the antibody comprising - a first infused amount of the antibody over a first infusion period using a first infusion rate, - a second infused amount of the antibody over a second infusion period using a second infusion rate, wherein the second infusion rate is higher than the first infusion rate.